Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Early Release)

HIV Surveillance Data Tables

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Early Release): National HIV Surveillance System Data Reported through December 2020; and Preexposure Prophylaxis (PrEP) Data Reported through September 2020

This issue of HIV Surveillance Data Tables is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2020 and preexposure prophylaxis (PrEP) data reported through September 2020.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (early release): National HIV Surveillance System data reported through December 2020; and preexposure prophylaxis (PrEP) data reported through September 2020. HIV Surveillance Data Tables 2021;2(No. 2). http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-2/index.html. Published March 2021. Accessed [date].

Download the full report pdf icon[PDF – 2 MB].

The Ending the HIV Epidemic: A Plan for America (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years, and by at least 90% in 10 years. The Centers for Disease Control and Prevention (CDC) routinely releases HIV Surveillance Data Tables on the core indicators for EHE to allow for more timely monitoring of progress.

The included early release tables provide national-, state-, and county-level (EHE Phase I jurisdictions only; see Table 7) data for the 6 core indicators of the EHE initiative, which are the following:

  • New HIV infections: the estimated number of new HIV infections in a calendar year.
  • Knowledge of HIV status: the estimated percentage of persons with HIV who have received a diagnosis.
  • HIV diagnoses: the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
  • Linkage to HIV medical care: the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
  • HIV viral suppression: the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
  • Preexposure prophylaxis (PrEP) coverage: the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

Surveillance of HIV Infection

Data presented were reported (after the removal of personally identifiable information) to the Centers for Disease Control and Prevention (CDC) through December 31, 2020. Please use caution when inter­preting the following:

  • Data on diagnoses of HIV infection. HIV surveil­lance reports may not be representative of all per­sons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not repre­sent all persons who tested positive for HIV infection.
  • Deaths and prevalence-based data (knowledge of status and HIV viral suppression). Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020.
  • Numbers less than 12 and trends based on these numbers.
  • All data for the year 2020 are considered preliminary (provided using an NHSS dataset produced prior to reaching a 12-month report­ing lag) and may be incomplete due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].

Tabulation and Presentation of Data

New HIV Infections

New HIV infections among persons aged ≥ 13 years are estimated using the first CD4+ T-lymphocyte (CD4) test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infec­tions can be found at Estimated HIV incidence and prevalence in the United States, 2014–2018 pdf icon[PDF – 2.5 MB].

HIV Prevalence and Diagnosed Infection

The Knowledge of HIV Status indicator is measured as the percentage of persons aged ≥ 13 years with diagnosed HIV infection (Tables 2a–c). For this mea­sure the numerator (data reported to CDC) is the num­ber of persons aged ≥ 13 years living with diagnosed HIV infection at the end of the year. The denominator, total HIV prevalence, is the estimated number of per­sons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at the end of the year. Knowledge of status and prevalence data for the year 2019 are pre­liminary and based on death data reported to CDC as of December 2020. The following areas had incom­plete reporting of deaths for the year 2019, and preva­lence estimates should be interpreted with caution: Kansas, Massachusetts, Mississippi, Nevada, North Dakota, and Vermont. Estimates for areas without laws requiring reporting of labora­tory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution. Areas without laws: Idaho and Pennsylvania (excluding Philadelphia). Areas with incomplete reporting: Kansas, Kentucky, New Jersey, Puerto Rico, and Vermont.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV infection can be found at Estimated HIV incidence and prevalence in the United States, 2014–2018 pdf icon[PDF – 2.5 MB].

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years with HIV diagnosed during 2017–2020 (Tables 3a–d).

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on counting diagnoses of HIV infection can be found at HIV Surveillance Report, 2018 [Updated].

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during January 2019 through September 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the specified period, and who had ≥ 1 CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the specified period. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through September of 2020 and that were reported to NHSS through December 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and Pennsylvania (excluding Philadelphia). Areas with incomplete reporting: Kansas, Kentucky, New Jersey, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached; preliminary data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

More information on calculating linkage to care can be found at Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018 pdf icon[PDF – 3.8 MB].

Viral Suppression

Viral suppression at most recent test during the specified year is measured for persons aged ≥ 13 years who resided, as of their most recent known address during the specified year, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC, and who were alive at the end of the specified year (Tables 5a–c). The numerator is the number of persons aged ≥ 13 years with HIV infection diagnosed by the end of the prior year, and who had a VL of < 200 copies/mL at the most recent test in the specified year. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed by the end of the prior year, and who were alive at the end of the specified year. Viral suppression data for the year 2019 are preliminary. Data used to calculate prevalence are based on deaths reported to CDC as of December 2020. The following areas had incomplete reporting of deaths for the year 2019, and viral suppression data should be interpreted with caution: Kansas, Massachusetts, Mississippi, Nevada, North Dakota, and Vermont. Data are not provided for states and associated EHE Phase I jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and Pennsylvania (excluding Philadelphia). Areas with incomplete lab reporting: Kansas, Kentucky, New Jersey, Puerto Rico, and Vermont.

More information on calculating viral suppression can be found at Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018 pdf icon[PDF – 3.8 MB].

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 6a–c).

Number of persons prescribed, which is reported as a case count, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year.

PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data-Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/ FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include white, black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic Designations

In the IQVIA database, a person’s location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau’s American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S Department of Housing and Urban Development’s ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

ACS and US Census Bureau files were used to estimate the number of MSM (men who have sex with men) in a jurisdiction [8.9].. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [10]. For the 2018 denominator, this proportion was updated with recent NHANES data.

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10. Beginning in 2017, methods were adjusted to provide the estimated number of persons of other races/ethnicities (including Asians and other race/ethnic groups), in addition to Blacks/African Americans, Hispanics/Latinos, and whites. Also beginning in 2017, an adjustment was applied to calculate an estimated number of persons with PrEP indications in counties with suppressed data for the number of HIV diagnoses in some transmission risk groups, age groups, or race/ethnicity groups.

The tables included in this report provide updated data on PrEP coverage for the year 2017 and 2018 and preliminary data for the year 2019 and for the year 2020 (from January through September) using the IQVIA data reported through September 2020. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary. For this release of HIV Surveillance Data Tables, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

More information on calculating PrEP coverage can be found at Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. pdf icon[PDF – 3.8 MB]

References

  1. HHS. What is ‘Ending the HIV Epidemic: A Plan for America’? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overviewexternal icon. Published October 4, 2019. February 4, 2021.
  2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2external icon
  3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis 2017; 64(2):144–149. doi:10.1093/cid/ciw701
  4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
  5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016– June 2018. Public Health Rep 2020;135(2):202–210. doi:10.1177/0033354920904085
  6. U.S. Census Bureau. American Community Survey 5-year data (2009-2018). https://www.census.gov/data/developers/data-sets/acs-5year.2016.htmlexternal icon. Published December 19, 2019. Accessed February 4, 2021.
  7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.htmlexternal icon. Published 2019. February 4, 2021.
  8. Grey JA, Bernstein KT, Sullivan PS, Purcell DW, Chesson HW, Gift TL, Rosenberg ES. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. JMIR public health and surveillance. 2016;2(1):e14.
  9. Purcell DW, Johnson CH, Lansky A, Prejean J, Stein R, Denning P, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J 2012;6:98-107
  10. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (early release): National HIV Surveillance System data reported through December 2020; and preexposure prophylaxis (PrEP) data reported through September 2020. HIV Surveillance Data Tables 2021;2(No. 2). http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-2/index.html. Published March 2021. Accessed [date].

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

Publication of HIV Surveillance Data Tables was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Rick Song, Baohua Wu, Xiaohong Hu, Jianmin Li, Shihua Wang, Chan Jin, Chenchen Yu, Weiming Zhu, Anne Patala, Lei Yu, Norma Harris, and Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).

Table 1a. Estimated HIV incidence among persons aged ≥13 years, by selected characteristics, 2017–2019—50 states and the District of Columbia
2017 2018 2019
No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
Sex at birth
Male 30,000 2.7 28,400 31,600 29,600 3.2 27,700 31,400 28,400 3.8 26,300 30,500
Female 6,700 5.1 6,100 7,400 6,700 5.7 5,900 7,400 6,400 6.6 5,600 7,200
Age at infection (yr)
13–24 8,600 4.9 7,700 9,400 7,800 6.1 6,800 8,700 7,200 7.4 6,200 8,300
25–34 14,100 3.9 13,000 15,200 14,300 4.5 13,000 15,500 13,800 5.3 12,400 15,300
35–44 6,700 5.6 5,900 7,400 6,900 6.4 6,100 7,800 6,900 7.4 5,900 7,900
45–54 4,400 6.9 3,800 5,000 4,200 8.1 3,600 4,900 3,800 9.9 3,100 4,600
≥55 3,000 8.5 2,500 3,400 3,100 9.5 2,500 3,600 3,100 10.9 2,400 3,800
Race/ethnicity
American Indian/Alaska Native 190 *33.5 70 320 210 *37.8 50 370 230 *41.2 40 420
Asian 620 19.2 380 850 580 23.2 320 850 550 26.8 260 840
Black/African American 14,900 3.7 13,800 16,000 14,800 4.3 13,500 16,000 14,300 5.1 12,900 15,700
Hispanic/Latinoa 10,800 4.7 9,800 11,800 11,000 5.5 9,800 12,200 10,200 6.7 8,900 11,600
Native Hawaiian/other Pacific Islander
White 9,100 4.5 8,300 9,800 8,700 5.3 7,800 9,600 8,600 6.1 7,600 9,600
Multiracial 1,100 14.3 810 1,400 940 17.9 610 1,300 900 20.9 530 1,300
Transmission categoryb
Male-to-male sexual contact 24,900 2.9 23,400 26,300 24,100 3.5 22,500 25,800 23,100 4.2 21,200 25,000
Injection drug use 2,300 8.5 1,900 2,700 2,500 9.5 2,000 3,000 2,500 11.3 1,900 3,000
      Male 1,300 12.3 970 1,600 1,500 13.2 1,100 1,800 1,400 16.2 940 1,800
      Female 1,000 11.2 810 1,300 1,000 13.1 770 1,300 1,100 15.4 750 1,400
Male-to-male sexual contact and injection drug use 1,300 11.1 1,000 1,600 1,400 11.8 1,100 1,800 1,400 13.4 1,100 1,800
Heterosexual contactc 8,200 5.3 7,300 9,000 8,200 5.9 7,200 9,100 7,800 6.8 6,700 8,800
      Male 2,500 11.5 1,900 3,100 2,600 12.7 1,900 3,200 2,400 14.5 1,700 3,100
      Female 5,700 5.6 5,000 6,300 5,600 6.4 4,900 6,300 5,300 7.4 4,600 6,100
Region of residence
Northeast 5,100 6.4 4,500 5,800 4,900 7.5 4,200 5,600 4,700 9.1 3,900 5,500
Midwest 4,900 6.5 4,200 5,500 4,700 7.6 4,000 5,400 4,500 9.0 3,700 5,300
South 19,200 3.3 17,900 20,400 19,100 3.9 17,600 20,500 18,500 4.5 16,800 20,100
West 7,500 5.3 6,800 8,300 7,600 6.2 6,700 8,500 7,100 7.4 6,100 8,200
Totald 36,700 2.4 35,000 38,400 36,200 2.8 34,300 38,200 34,800 3.3 32,600 37,100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage (footnotes only). Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.
Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.
Estimates with an RSE>50% are not shown and are replaced with an ellipsis (…).

aHispanic/Latino persons can be of any race.
bData by transmission category have been statistically adjusted to account for missing risk-factor information.
cHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
dIncludes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or not identified.

Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2019—50 states, the District of Columbia, and Puerto Rico
2017 2018 2019
Area of residence No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
Alabama 630 18.1 400 850 600 21.3 350 850 570 25.7 280 860
Alaska
Arizona 840 16.4 570 1,100 870 19.0 550 1,200 800 23.2 440 1,200
Arkansas 300 28.0 130 460 240 *37.3 60 410 330 *35.3 100 560
California 4,600 6.6 4,000 5,200 4,500 7.6 3,900 5,200 4,000 9.6 3,300 4,800
Colorado 440 22.4 250 630 430 26.5 210 650 510 28.2 230 800
Connecticut 250 28.6 110 380 190 *39.4 40 340 160 *49.4 0 320
Delaware 120 *36.8 30 210
District of Columbia 210 29.7 90 330 230 29.9 100 370 190 *38.2 50 330
Florida 4,400 6.4 3,900 5,000 4,300 7.5 3,700 4,900 4,000 8.9 3,300 4,700
Georgia 2,500 9.2 2,100 3,000 2,500 11.0 2,000 3,000 2,400 13.1 1,800 3,000
Hawaii 100 *44.8 10 180
Idahoa
Illinois 1,300 12.6 970 1,600 1,300 14.4 930 1,700 1,200 17.7 790 1,600
Indiana 530 21.1 310 750 580 22.6 330 840 540 28.3 240 850
Iowa 100 *49.9 0 210
Kansasa 210 *42.3 40 390
Kentuckya 310 26.1 150 470 420 24.2 220 620 340 *33.1 120 560
Louisiana 1,000 15.0 700 1,300 1,100 16.5 720 1,400 870 22.3 490 1,300
Maine
Maryland 760 16.7 510 1,000 830 17.2 550 1,100 740 21.0 430 1,000
Massachusetts 570 18.3 360 770 680 18.2 430 920 530 24.6 270 780
Michigan 720 17.3 470 960 670 20.8 400 950 630 25.0 320 930
Minnesota 250 29.2 110 390 290 *31.4 110 470 260 *37.8 70 450
Mississippi 480 26.1 230 720 440 *32.4 160 720 550 *32.9 190 900
Missouri 520 17.9 340 700 480 22.5 270 690 450 26.3 220 680
Montana
Nebraska 110 *42.9 20 200
Nevada 570 20.9 330 800 610 23.3 330 890 740 25.0 380 1,100
New Hampshire
New Jerseya 1,100 15.6 750 1,400 960 19.0 600 1,300 990 20.8 590 1,400
New Mexico 140 *35.6 40 230 180 *35.7 60 310 170 *44.0 20 310
New York 2,200 9.5 1,800 2,600 2,000 11.5 1,600 2,500 1,800 13.9 1,300 2,300
North Carolina 1,200 12.0 900 1,500 1,100 14.7 760 1,400 1,200 14.9 860 1,600
North Dakota
Ohio 970 14.7 690 1,300 890 17.8 580 1,200 870 20.6 520 1,200
Oklahoma 320 25.1 160 470 300 *31.6 110 490 370 *33.3 130 610
Oregon 210 *31.9 80 340 190 *39.5 *40 340 200 *44.1 30 380
Pennsylvaniaa 970 19.0 610 1,300 980 20.5 590 1,400 800 22.1 450 1,100
Puerto Ricoa 400 22.9 220 580 320 28.7 140 510 280 *35.4 90 480
Rhode Island 80 *47.2 10 150
South Carolina 700 19.3 430 960 690 22.8 380 1,000 710 25.5 350 1,100
South Dakota
Tennessee 700 15.7 490 920 660 18.6 420 900 710 19.6 440 980
Texas 4,400 6.9 3,800 5,000 4,500 7.8 3,800 5,200 4,500 9.2 3,700 5,300
Utah 110 *42.6 20 200 130 *43.2 20 250 150 *47.3 10 290
Vermonta
Virginia 850 15.3 600 1,100 800 18.1 520 1,100 760 21.2 440 1,100
Washington 480 21.2 280 680 520 23.3 280 760 540 27.3 250 830
West Virginia 80 *50.0 0 170 110 *48.1 10 220 210 *40.7 40 380
Wisconsin 240 28.2 110 370 190 *38.5 50 330 210 *41.1 40 370
Wyoming

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage (footnotes only).
Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.
Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.
Estimates with an RSE>50% are not shown and are replaced with an ellipsis (…).

aEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I Jurisdictions
2017 2018 2019
Area of residence No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
     Arizona
     Maricopa County 560 19.2 350 760 560 22.4 320 810 520 27.6 240 800
     California
     Alameda County 180 *32.6 60 290 180 *36.7 50 320 200 *41.3 40 360
     Los Angeles County 1,400 11.4 1,100 1,800 1,400 13.1 1,100 1,800 1,300 16.0 900 1,700
     Orange County 270 26.3 130 410 270 *30.4 110 430 200 *40.7 40 370
     Riverside County 270 26.5 130 410 270 *30.0 110 440 260 *35.9 80 440
     Sacramento County 220 29.2 90 350 160 *39.4 40 280 140 *48.6 10 280
     San Bernardino County 260 26.9 120 400 240 *31.9 90 390 300 *33.6 100 490
     San Diego County 450 20.5 270 630 430 24.2 220 630 360 *30.7 140 570
     San Francisco County 170 *33.3 60 280 150 *40.4 30 270
     District of Columbia 210 29.7 90 330 230 29.9 100 370 190 *38.2 50 330
     Florida
     Broward County 650 16.0 450 860 550 20.0 340 770 560 22.8 310 810
     Duval County 260 25.5 130 390 230 *31.0 90 370 190 *39.2 40 340
     Hillsborough County 290 24.2 150 420 270 28.4 120 430 210 *37.1 60 370
     Miami-Dade County 1,200 12.0 890 1,400 1,100 13.9 840 1,500 1,100 16.4 740 1,400
     Orange County 430 19.8 260 600 450 22.2 250 650 450 25.4 230 680
     Palm Beach County 260 25.3 130 390 250 29.8 100 400 230 *36.0 70 390
     Pinellas County 150 *33.6 50 250 140 *40.2 30 240 150 *44.6 20 280
     Georgia
     Cobb County 170 *33.2 60 290 160 *41.6 30 280 220 *41.3 40 390
     DeKalb County 340 23.8 180 500 390 26.2 190 590 330 *33.4 110 550
     Fulton County 570 18.4 360 770 620 20.8 370 870 500 27.2 230 770
     Gwinnett County 160 *34.4 50 270 140 *43.6 20 260 200 *42.7 30 370
     Illinois
     Cook County 940 14.5 680 1,200 890 17.4 580 1,200 870 20.7 520 1,200
     Indiana
     Marion County 230 29.0 100 350 250 *31.4 100 400 250 *38.9 60 430
     Louisiana
     East Baton Rouge Parish 180 *31.5 70 290 190 *34.3 60 320 180 *42.1 30 330
     Orleans Parish 160 *32.8 60 270 160 *37.6 40 280 140 *47.6 10 270
     Maryland
     Baltimore City 190 *34.1 60 310 210 *34.0 70 350 140 *49.0 10 280
     Montgomery County 110 *45.0 10 200
     Prince George’s County 190 *33.7 60 320 260 *30.3 110 420 240 *37.2 70 420
     Massachusetts
     Suffolk County 130 *36.7 40 230 140 *37.8 40 250 140 *43.5 20 260
     Michigan
     Wayne County 290 24.8 150 430 270 29.8 110 430 300 *32.9 100 490
     Nevada
     Clark County 500 21.8 290 720 550 24.1 290 820 630 27.0 300 970
     New Jersey
     Essex Countya 310 26.6 150 480 230 *36.5 70 390 210 *43.5 30 390
     Hudson Countya 160 *37.5 40 280 170 *41.7 30 320
     New York
     Bronx County 380 21.8 220 550 410 24.0 220 600 400 28.7 170 620
     Kings County 490 19.2 310 680 470 22.6 260 670 370 29.6 160 590
     New York County 340 23.0 190 500 280 28.9 120 440 270 *35.1 80 450
     Queens County 340 23.3 180 490 300 28.2 130 460 220 *38.7 50 380
     North Carolina
     Mecklenburg County 270 22.9 150 400 190 *36.4 50 330 220 *35.2 70 380
     Ohio
     Cuyahoga County 140 *39.4 30 240 110 *49.8 0 220
     Franklin County 200 *32.2 80 330 210 *35.9 60 360 210 *40.7 40 390
     Hamilton County 170 *35.5 50 290 150 *43.1 20 280
     Pennsylvania
     Philadelphia County 400 18.5 260 550 400 20.9 230 560 400 23.9 210 580
     Puerto Rico
     San Juan Municipioa 100 *43.5 10 180
     Tennessee
     Shelby County 220 27.9 100 330 220 29.5 90 350 230 *32.0 90 370
     Texas
     Bexar County 310 25.7 150 460 340 28.3 150 520 380 *31.5 140 610
     Dallas County 810 15.8 560 1,100 820 18.1 530 1,100 610 24.9 310 900
     Harris County 1,100 13.3 840 1,400 1,200 15.1 840 1,500 1,200 17.6 800 1,600
     Tarrant County 300 25.8 150 460 270 *31.4 100 440 340 *33.2 120 560
     Travis County 210 *31.0 80 340 240 *33.3 *80 400 190 *44.9 20 350
     Washington
     King County 220 *31.1 80 350 290 *30.0 120 460 240 *41.9 40 450

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.
Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.
Estimates with an RSE>50% are not shown and are replaced with an ellipsis (…).

aEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Area without laws: New Jersey. Areas with incomplete reporting: Pennsylvania (excluding Philadelphia County) and Puerto Rico.

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2019 —50 states and the District of Columbia
2017
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE 95% CI No.a % RSE 95% CI
Sex at birth
Male 889,600 0.4 883,200 896,000 756,245 85.0 0.4 84.4 85.6
Female 257,500 0.6 254,300 260,600 229,677 89.2 0.6 88.1 90.3
Age at infection (yr)
13–24 58,300 1.3 56,800 59,800 27,471 47.1 1.3 45.9 48.4
25–34 206,800 0.6 204,400 209,200 148,259 71.7 0.6 70.9 72.5
35–44 219,100 0.5 217,100 221,200 187,196 85.4 0.5 84.6 86.2
45–54 316,300 0.4 314,000 318,600 292,913 92.6 0.4 91.9 93.3
≥55 346,500 0.4 343,500 349,500 330,083 95.3 0.4 94.5 96.1
Race/ethnicity
American Indian/Alaska Native 3,700 5.8 3,200 4,100 2,890 79.1 5.9 71.0 89.2
Asianb 16,500 2.4 15,700 17,300 13,703 83.0 2.4 79.2 87.1
Black/African American 462,800 0.5 458,200 467,300 396,794 85.7 0.5 84.9 86.6
Hispanic/Latino c 277,000 0.6 273,700 280,400 229,451 82.8 0.6 81.8 83.8
Native Hawaiian/other Pacific Islander 1,000 10.4 800 1,200 800 79.2 10.9 65.7 99.6
White 331,100 0.6 327,100 335,000 293,375 88.6 0.6 87.6 89.7
Multiracial 54,300 1.3 52,900 55,700 48,185 88.8 1.3 86.6 91.1
Transmission categoryd
Male-to-male sexual contact 657,800 0.4 652,500 663,100 551,337 83.8 0.4 83.1 84.5
Injection drug use 126,100 1.1 123,400 128,800 117,609 93.3 1.1 91.3 95.3
      Male 73,900 1.5 71,800 76,100 68,695 93.0 1.5 90.3 95.7
      Female 52,200 1.5 50,600 53,800 48,914 93.7 1.5 90.9 96.6
Male-to-male sexual contact and injection drug use 61,600 1.4 59,900 63,200 56,526 91.8 1.4 89.4 94.3
Heterosexual contacte 298,200 0.6 294,700 301,700 257,233 86.3 0.6 85.3 87.3
      Male 94,300 1.2 92,100 96,400 77,740 82.5 1.2 80.6 84.4
      Female 203,900 0.7 201,200 206,700 179,492 88.0 0.7 86.9 89.2
Region of residence
Northeast 250,900 0.7 247,500 254,300 227,889 90.8 0.7 89.6 92.1
Midwest 139,900 0.9 137,400 142,400 117,771 84.2 0.9 82.7 85.7
South 527,400 0.5 522,600 532,200 444,756 84.3 0.5 83.6 85.1
West 228,900 0.7 225,700 232,000 195,506 85.4 0.7 84.3 86.6
Totalf 1,147,100 0.3 1,139,900 1,154,200 985,922 86.0 0.3 85.4 86.5
Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2019 —50 states and the District of Columbia
2018
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE 95% CI No.a % RSE 95% CI
Sex at birth
Male 908,000 0.4 901,400 914,700 775,373 85.4 0.4 84.8 86.0
Female 260,600 0.6 257,400 263,900 233,277 89.5 0.6 88.4 90.6
Age at infection (yr)
13–24 51,800 1.6 50,200 53,400 26,319 50.8 1.6 49.2 52.5
25–34 214,000 0.7 211,200 216,700 153,015 71.5 0.7 70.6 72.4
35–44 222,900 0.5 220,600 225,200 189,585 85.0 0.5 84.2 85.9
45–54 303,500 0.4 301,100 305,900 280,939 92.6 0.4 91.8 93.3
≥55 376,500 0.4 373,300 379,600 358,792 95.3 0.4 94.5 96.1
Race/ethnicity
American Indian/Alaska Native 3,800 5.9 3,400 4,300 3,026 79.2 6.0 70.9 89.6
Asianb 17,100 2.5 16,300 17,900 14,556 85.1 2.5 81.2 89.5
Black/African American 471,100 0.5 466,400 475,800 405,759 86.1 0.5 85.3 87.0
Hispanic/Lationc 286,000 0.6 282,400 289,600 237,914 83.2 0.6 82.2 84.3
Native Hawaiian/other Pacific Islander 1,100 10.8 850 1,300 853 81.0 10.4 66.8 100.0
White 334,800 0.6 330,700 338,800 297,674 88.9 0.6 87.9 90.0
Multiracial 54,200 1.4 52,700 55,600 48,144 88.9 1.4 86.6 91.3
Transmission categoryd
Male-to-male sexual contact 675,700 0.4 670,100 681,300 569,690 84.3 0.4 83.6 85.0
Injection drug use 125,300 1.1 122,600 128,000 116,779 93.2 1.1 91.2 95.3
      Male 73,300 1.5 71,100 75,500 68,046 92.8 1.5 90.1 95.7
      Female 52,000 1.6 50,400 53,600 48,733 93.7 1.6 90.9 96.7
Male-to-male sexual contact and injection drug use 61,600 1.4 59,900 63,300 56,545 91.8 1.4 89.3 94.3
Heterosexual contacte 302,700 0.6 299,100 306,300 262,443 86.7 0.6 85.7 87.8
      Male 95,300 1.2 93,100 97,600 79,170 83.0 1.2 81.1 85.0
      Female 207,400 0.7 204,500 210,200 183,273 88.4 0.7 87.2 89.6
Region of residence
Northeast 252,300 0.7 248,900 255,800 229,996 91.1 0.7 89.9 92.4
Midwest 142,700 0.9 140,100 145,300 120,835 84.7 0.9 83.2 86.2
South 539,400 0.5 534,300 544,400 456,972 84.7 0.5 83.9 85.5
West 234,300 0.7 231,000 237,500 200,847 85.7 0.7 84.5 87.0
Totalf 1,168,700 0.3 1,161,200 1,176,100 1,008,650 86.3 0.3 85.8 86.9
Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2019 —50 states and the District of Columbia
2019
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
No. RSE 95% CI No.a % RSE 95% CI
Sex at birth
Male 925,800 0.4 918,800 932,800 794,128 85.8 0.4 85.1 86.4
Female 263,900 0.7 260,600 267,300 237,063 89.8 0.7 88.7 91.0
Age at infection (yr)
13–24 45,900 2.0 44,100 47,700 25,581 55.7 2.0 53.6 58.0
25–34 218,700 0.7 215,600 221,800 156,378 71.5 0.7 70.5 72.5
35–44 228,000 0.6 225,500 230,500 192,894 84.6 0.6 83.7 85.6
45–54 290,000 0.4 287,500 292,400 268,039 92.4 0.4 91.7 93.2
≥55 407,100 0.4 403,800 410,400 388,299 95.4 0.4 94.6 96.2
Race/ethnicity
American Indian/Alaska Native 4,000 6.2 3,500 4,500 3,185 79.5 6.3 71.0 90.5
Asianb 17,700 2.6 16,800 18,600 15,309 86.6 2.6 82.5 91.2
Black/African American 479,300 0.5 474,400 484,300 415,003 86.6 0.5 85.7 87.5
Hispanic/Latinoc 294,200 0.7 290,400 298,100 246,078 83.6 0.7 82.6 84.7
Native Hawaiian/other Pacific Islander 1,100 11.2 910 1,300 906 83.6 9.6 68.5 100.0
White 338,600 0.6 334,400 342,800 301,927 89.2 0.6 88.1 90.3
Multiracial 54,100 1.4 52,600 55,500 48,063 88.9 1.4 86.5 91.4
Transmission categoryd
Male-to-male sexual contact 692,900 0.4 686,900 698,800 587,555 84.8 0.4 84.1 85.5
Injection drug use 124,700 1.1 122,000 127,500 116,263 93.2 1.1 91.2 95.3
      Male 72,900 1.6 70,600 75,100 67,603 92.8 1.6 90.0 95.7
      Female 51,900 1.6 50,200 53,500 48,660 93.8 1.6 90.9 96.8
Male-to-male sexual contact and injection drug use 61,800 1.4 60,000 63,500 56,720 91.8 1.4 89.3 94.5
Heterosexual contacte 307,000 0.6 303,300 310,800 267,478 87.1 0.6 86.1 88.2
      Male 96,300 1.2 93,900 98,600 80,351 83.4 1.2 81.5 85.5
      Female 210,700 0.7 207,800 213,700 187,127 88.8 0.7 87.6 90.1
Region of residence
Northeast 253,600 0.7 250,000 257,200 231,873 91.4 0.7 90.1 92.7
Midwest 145,100 0.9 142,500 147,800 123,501 85.1 0.9 83.5 86.7
South 551,600 0.5 546,300 556,900 469,803 85.2 0.5 84.4 86.0
West 239,400 0.7 235,900 242,800 206,014 86.1 0.7 84.8 87.3
Totalf 1,189,700 0.3 1,181,900 1,197,500 1,031,191 86.7 0.3 86.1 87.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage (footnotes only).
Note. Data for the year 2019 data are preliminary and based on deaths reported to CDC as of December 2020. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.
Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.
Estimates with an RSE>50% are not shown and are replaced with an ellipsis (…).

aReported to the National HIV Surveillance System.
bIncludes Asian/Pacific Islander legacy cases.
cHispanic/Latino persons can be of any race.
dData by transmission category have been statistically adjusted to account for missing risk-factor information.
eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
fIncludes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or not identified.

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—50 states, the District of Columbia, and Puerto Rico
2017
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Alabama 15,700 2.7 14,900 16,600 12,930 82.1 2.7 78.0 86.8
Alaska 810 11.4 700 990 704 87.1 8.4 71.2 100
Arizona 18,900 2.4 18,100 19,800 15,727 83.0 2.4 79.3 87.0
Arkansas 6,900 4.0 6,300 7,400 5,534 80.6 4.0 74.7 87.5
California 146,400 0.9 143,800 148,900 127,097 86.8 0.9 85.4 88.4
Colorado 14,000 2.7 13,300 14,700 12,106 86.6 2.7 82.2 91.3
Connecticut 11,300 3.2 10,600 12,000 10,144 89.9 3.2 84.6 95.9
Delaware 3,600 5.5 3,200 4,000 3,219 88.4 5.6 79.8 99.2
District of Columbia 15,100 2.8 14,300 15,900 14,066 93.3 2.8 88.5 98.7
Florida 125,700 1.0 123,400 128,100 107,614 85.6 1.0 84.0 87.2
Georgia 63,400 1.3 61,800 64,900 52,366 82.7 1.3 80.6 84.8
Hawaii 2,800 6.4 2,400 3,100 2,413 87.1 6.6 77.4 99.8
Idahob 1,400 10.1 1,100 1,600 1,109 81.5 10.0 68.0 100
Illinois 40,300 1.7 39,000 41,600 34,661 86.0 1.7 83.2 89.0
Indiana 13,200 2.9 12,500 14,000 10,945 82.7 2.9 78.3 87.7
Iowa 3,100 5.5 2,800 3,500 2,638 84.0 5.6 75.7 94.2
Kansasbc 3,600 5.7 3,200 4,000 2,959 82.2 5.8 73.9 92.6
Kentuckyb 8,500 3.5 7,900 9,000 7,000 82.6 3.5 77.4 88.6
Louisiana 24,400 2.2 23,300 25,500 20,129 82.5 2.3 79.0 86.3
Maine 1,800 7.7 1,500 2,000 1,545 87.4 7.0 76.0 100
Maryland 36,300 1.8 35,100 37,600 32,116 88.4 1.8 85.4 91.6
Massachusettsc 22,400 2.2 21,500 23,400 20,032 89.4 2.2 85.8 93.4
Michigan 18,600 2.6 17,700 19,600 15,471 83.0 2.6 79.1 87.5
Minnesota 9,400 3.2 8,800 10,000 8,155 86.9 3.2 81.8 92.7
Mississippic 11,600 3.4 10,800 12,300 9,203 79.6 3.4 74.6 85.3
Missouri 14,000 2.8 13,200 14,800 12,149 86.8 2.8 82.3 91.8
Montana 710 10.6 620 850 615 87.0 8.2 72.0 100
Nebraska 2,500 6.4 2,200 2,800 2,087 84.1 6.5 74.8 96.2
Nevadac 11,700 3.0 11,000 12,400 9,473 81.0 3.0 76.6 86.1
New Hampshire 1,300 8.8 1,200 1,500 1,161 89.7 6.7 76.4 100
New Jerseyb 38,800 1.9 37,300 40,300 34,058 87.8 2.0 84.6 91.3
New Mexico 3,900 4.9 3,500 4,300 3,385 86.4 4.9 78.8 95.6
New York 133,800 0.9 131,400 136,300 123,071 92.0 0.9 90.3 93.7
North Carolina 35,300 1.7 34,100 36,400 30,468 86.4 1.7 83.6 89.3
North Dakotac 620 16.2 420 820 400 64.3 18.1 48.7 94.3
Ohio 26,000 2.0 25,000 27,000 21,663 83.4 2.0 80.2 86.8
Oklahoma 7,200 4.0 6,600 7,800 5,942 82.6 4.1 76.6 89.7
Oregon 7,800 3.5 7,300 8,300 6,822 87.6 3.5 81.9 94.0
Pennsylvaniab 39,200 1.8 37,900 40,600 34,703 88.5 1.8 85.5 91.7
Puerto Ricob 17,500 3.1 16,500 18,600 15,665 89.4 3.1 84.3 95.1
Rhode Island 2,800 6.0 2,500 3,100 2,497 88.7 6.0 79.3 100
South Carolina 19,900 2.4 18,900 20,800 16,466 82.8 2.4 79.0 86.9
South Dakota 740 12.5 570 920 567 76.5 12.8 61.5 100
Tennessee 19,400 2.4 18,500 20,300 16,461 85.0 2.4 81.2 89.2
Texas 106,000 1.0 103,900 108,100 87,393 82.5 1.0 80.9 84.1
Utah 3,200 5.7 2,900 3,600 2,718 83.8 5.7 75.4 94.2
Vermontbc 770 10.5 680 920 678 88.5 7.7 73.4 100
Virginia 25,600 2.1 24,600 26,700 22,073 86.1 2.1 82.7 89.7
Washington 15,000 2.6 14,200 15,700 13,019 87.1 2.6 82.8 91.8
West Virginia 2,100 7.1 1,800 2,400 1,776 83.1 7.3 72.9 96.6
Wisconsin 7,000 3.8 6,500 7,600 6,076 86.3 3.8 80.3 93.2
Wyoming 370 16.1 320 480 318 87.0 9.9 66.1 100
Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—50 states, the District of Columbia, and Puerto Rico
2018
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Alabama 16,200 2.8 15,300 17,100 13,371 82.6 2.8 78.4 87.4
Alaska 810 11.8 700 1,000 697 86.3 8.9 70.0 100
Arizona 19,700 2.4 18,800 20,600 16,357 83.1 2.4 79.3 87.2
Arkansas 7,000 4.2 6,400 7,500 5,670 81.4 4.2 75.3 88.7
California 148,900 0.9 146,200 151,500 129,772 87.2 0.9 85.7 88.7
Colorado 14,500 2.7 13,700 15,200 12,552 86.8 2.7 82.4 91.7
Connecticut 11,400 3.3 10,600 12,100 10,284 90.6 3.3 85.1 96.8
Delaware 3,700 5.7 3,300 4,100 3,246 88.7 5.7 79.8 99.8
District of Columbia 14,900 2.8 14,100 15,700 13,940 93.6 2.9 88.7 99.1
Florida 127,600 1.0 125,100 130,000 109,691 86.0 1.0 84.4 87.7
Georgia 65,200 1.3 63,500 66,900 54,219 83.1 1.3 81.1 85.3
Hawaii 2,700 6.8 2,400 3,100 2,358 87.5 6.7 77.1 100.0
Idahob 1,400 10.6 1,200 1,700 1,155 81.5 10.2 67.5 100
Illinois 41,000 1.7 39,700 42,400 35,482 86.4 1.7 83.6 89.5
Indiana 13,600 3.0 12,900 14,400 11,289 82.7 3.0 78.1 87.9
Iowa 3,300 5.7 2,900 3,600 2,750 84.3 5.8 75.8 94.9
Kansasbc 3,700 6.0 3,200 4,100 3,044 83.3 6.1 74.6 94.3
Kentuckyb 8,800 3.5 8,200 9,400 7,264 82.7 3.6 77.3 88.9
Louisiana 25,000 2.3 23,900 26,100 20,609 82.5 2.3 78.9 86.4
Maine 1,800 7.8 1,600 2,100 1,594 87.9 6.9 76.2 100
Maryland 36,700 1.8 35,400 38,000 32,645 88.9 1.8 85.9 92.2
Massachusettsc 22,700 2.2 21,800 23,700 20,344 89.5 2.2 85.8 93.5
Michigan 18,900 2.6 17,900 19,900 15,782 83.5 2.7 79.4 88.1
Minnesota 9,700 3.3 9,000 10,300 8,431 87.3 3.3 82.0 93.2
Mississippic 11,700 3.6 10,900 12,500 9,395 80.2 3.6 74.9 86.3
Missouri 14,300 2.8 13,500 15,100 12,461 86.9 2.8 82.3 92.0
Montana 730 10.8 640 890 638 87.1 8.3 71.8 100
Nebraska 2,500 6.6 2,200 2,800 2,133 85.0 6.7 75.2 97.6
Nevadac 12,400 3.0 11,700 13,200 10,085 81.2 3.1 76.7 86.4
New Hampshire 1,300 8.7 1,200 1,600 1,227 91.0 6.2 77.7 100
New Jerseyb 38,800 2.0 37,300 40,400 34,171 88.0 2.0 84.6 91.6
New Mexico 4,100 4.9 3,700 4,500 3,564 86.0 4.9 78.4 95.1
New York 134,100 0.9 131,600 136,600 123,796 92.3 0.9 90.6 94.0
North Carolina 36,100 1.7 34,800 37,300 31,371 87.0 1.7 84.2 90.0
North Dakotac 690 17.2 450 920 440 64.1 19.5 47.9 96.7
Ohio 26,500 2.1 25,400 27,500 22,215 84.0 2.1 80.7 87.6
Oklahoma 7,400 4.1 6,800 8,000 6,109 82.8 4.2 76.6 90.1
Oregon 7,900 3.6 7,400 8,500 7,008 88.3 3.6 82.5 94.9
Pennsylvaniab 39,800 1.8 38,400 41,300 35,333 88.7 1.8 85.6 92.0
Puerto Ricob 17,300 3.2 16,200 18,400 15,520 89.8 3.2 84.6 95.8
Rhode Island 2,800 6.1 2,500 3,200 2,549 89.5 5.7 79.9 100
South Carolina 20,300 2.5 19,300 21,300 16,902 83.2 2.5 79.3 87.5
South Dakota 780 12.7 600 980 603 77.0 12.7 61.7 100
Tennessee 19,900 2.4 18,900 20,800 17,058 85.8 2.4 81.9 90.1
Texas 109,600 1.0 107,400 111,900 90,938 82.9 1.0 81.3 84.7
Utah 3,400 5.6 3,100 3,800 2,901 84.3 5.7 75.9 94.7
Vermontbc 780 10.7 700 940 698 89.5 7.4 74.0 100
Virginia 26,200 2.1 25,100 27,300 22,673 86.6 2.1 83.1 90.3
Washington 15,400 2.7 14,600 16,200 13,421 87.2 2.7 82.9 92.1
West Virginia 2,300 7.2 1,900 2,600 1,871 82.7 7.3 72.5 96.3
Wisconsin 7,200 3.9 6,600 7,700 6,205 86.8 3.9 80.6 93.9
Wyoming 390 15.9 340 510 339 86.6 10.0 66.0 100
Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—50 states, the District of Columbia, and Puerto Rico
2019
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Alabama 16,500 2.9 15,600 17,400 13,767 83.4 2.9 79.0 88.4
Alaska 830 12.1 720 1,000 715 85.7 9.1 69.3 100
Arizona 20,500 2.5 19,500 21,500 17,132 83.5 2.5 79.6 87.8
Arkansas 7,200 4.3 6,600 7,800 5,892 81.5 4.4 75.1 89.1
California 150,900 0.9 148,100 153,600 132,146 87.6 0.9 86.0 89.2
Colorado 14,900 2.8 14,100 15,700 12,934 86.8 2.8 82.3 91.9
Connecticut 11,400 3.3 10,700 12,200 10,412 91.1 3.3 85.5 97.4
Delaware 3,700 5.7 3,300 4,200 3,332 89.2 5.7 80.2 100.0
District of Columbia 14,800 2.9 14,000 15,600 13,913 94.0 2.9 88.9 99.7
Florida 129,500 1.0 127,000 132,100 112,046 86.5 1.0 84.8 88.2
Georgia 66,900 1.4 65,100 68,700 55,933 83.6 1.4 81.5 85.9
Hawaii 2,700 7.1 2,400 3,100 2,369 87.8 6.7 77.1 100.0
Idahob 1,500 10.8 1,200 1,800 1,213 82.3 9.9 67.9 100
Illinois 41,000 1.8 39,600 42,500 35,504 86.5 1.8 83.6 89.7
Indiana 13,900 3.1 13,100 14,800 11,507 82.6 3.2 77.8 88.1
Iowa 3,400 5.9 3,000 3,800 2,852 83.5 6.0 74.8 94.5
Kansasbc 3,800 6.2 3,400 4,300 3,140 82.0 6.3 73.1 93.3
Kentuckyb 9,100 3.6 8,500 9,800 7,570 83.2 3.7 77.6 89.6
Louisiana 25,500 2.4 24,300 26,700 21,117 82.9 2.4 79.1 86.9
Maine 1,800 8.0 1,600 2,100 1,629 89.2 6.6 77.0 100
Maryland 36,700 1.8 35,400 38,100 32,863 89.4 1.9 86.3 92.8
Massachusettsc 23,100 2.2 22,100 24,100 20,734 89.7 2.2 85.9 93.8
Michigan 19,500 2.7 18,400 20,500 16,390 84.2 2.7 80.0 88.9
Minnesota 9,900 3.3 9,300 10,600 8,695 87.8 3.3 82.4 93.9
Mississippic 12,100 3.8 11,200 13,000 9,712 80.3 3.8 74.7 86.7
Missouri 14,500 2.9 13,700 15,400 12,703 87.3 2.9 82.6 92.6
Montana 750 11.1 670 920 666 88.5 7.9 72.7 100
Nebraska 2,600 6.9 2,200 2,900 2,204 85.1 7.0 75.0 98.3
Nevadac 13,200 3.2 12,400 14,000 10,650 80.6 3.2 75.8 86.0
New Hampshire 1,400 8.6 1,300 1,600 1,283 91.9 5.9 78.6 100
New Jerseyb 39,200 2.1 37,600 40,700 34,555 88.2 2.1 84.8 92.0
New Mexico 4,300 5.0 3,900 4,700 3,710 86.2 5.1 78.5 95.7
New York 133,900 1.0 131,300 136,400 124,048 92.7 1.0 90.9 94.5
North Carolina 37,200 1.7 35,900 38,500 32,646 87.8 1.7 84.9 90.9
North Dakotac 750 18.5 480 1,000 484 64.1 21.1 47.1 100.0
Ohio 27,100 2.2 25,900 28,200 22,963 84.8 2.2 81.3 88.5
Oklahoma 7,600 4.3 7,000 8,300 6,299 82.7 4.4 76.2 90.4
Oregon 8,200 3.7 7,600 8,700 7,227 88.6 3.7 82.6 95.4
Pennsylvaniab 40,200 1.9 38,700 41,700 35,897 89.3 1.9 86.1 92.7
Puerto Ricob 17,300 3.2 16,200 18,300 15,595 90.4 3.2 85.0 96.5
Rhode Island 2,900 6.2 2,600 3,300 2,605 89.8 5.7 80.0 100
South Carolina 20,800 2.6 19,800 21,900 17,393 83.5 2.6 79.4 88.0
South Dakota 810 13.0 640 1,000 638 78.6 12.1 62.6 100
Tennessee 20,200 2.5 19,300 21,200 17,491 86.4 2.5 82.4 90.8
Texas 113,300 1.1 111,000 115,700 94,449 83.3 1.1 81.6 85.1
Utah 3,600 5.7 3,200 4,000 3,051 84.6 5.8 76.0 95.3
Vermontbc 790 11.0 710 960 710 89.6 7.5 73.7 100
Virginia 26,900 2.2 25,700 28,000 23,413 87.2 2.2 83.6 91.0
Washington 15,900 2.8 15,000 16,700 13,866 87.3 2.8 82.8 92.3
West Virginia 2,400 7.6 2,100 2,800 1,967 81.2 7.8 70.6 95.4
Wisconsin 7,400 4.0 6,800 7,900 6,421 87.2 4.0 80.9 94.5
Wyoming 380 16.9 340 510 335 87.4 10.0 65.6 100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage (footnotes only).
Note. Estimates for the year 2019 data are preliminary and based on deaths reported to CDC as of December 2020. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.
Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.
Estimates with an RSE>50% are not shown and are replaced with an ellipsis (…).

aReported to the National HIV Surveillance System.
bEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.
cEstimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions
2017
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Arizona
Maricopa County 13,000 2.9 12,200 13,700 10,775 83.2 2.9 78.7 88.1
California
Alameda County 6,700 4.1 6,200 7,300 5,847 86.8 4.1 80.4 94.5
Los Angeles County 54,000 1.4 52,500 55,500 47,867 88.6 1.4 86.2 91.2
Orange County 8,100 3.8 7,500 8,700 6,742 83.3 3.8 77.5 89.9
Riverside County 9,500 2.7 9,000 10,000 8,507 89.3 2.7 84.7 94.3
Sacramento County 4,900 4.5 4,400 5,300 4,159 85.3 4.6 78.3 93.7
San Bernardino County 5,100 4.6 4,700 5,600 4,088 79.9 4.6 73.3 87.8
San Diego County 15,100 2.6 14,300 15,900 12,889 85.3 2.7 81.1 90.0
San Francisco County 13,000 3.4 12,300 13,900 12,304 94.8 3.0 88.8 100
District of Columbia 15,100 2.8 14,300 15,900 14,066 93.3 2.8 88.5 98.7
Florida
Broward County 21,600 2.2 20,600 22,500 19,006 88.1 2.2 84.5 92.1
Duval County 7,100 4.0 6,500 7,700 5,839 82.2 4.0 76.2 89.3
Hillsborough County 7,800 3.8 7,200 8,400 6,581 84.6 3.8 78.7 91.5
Miami-Dade County 29,800 2.1 28,600 31,000 25,691 86.3 2.1 82.9 90.0
Orange County 9,900 3.3 9,300 10,600 8,280 83.4 3.4 78.3 89.3
Palm Beach County 8,900 3.7 8,200 9,500 7,733 87.0 3.7 81.2 93.9
Pinellas County 5,200 4.4 4,700 5,600 4,454 86.3 4.5 79.4 94.6
Georgia
Cobb County 3,600 4.9 3,300 4,000 2,999 82.9 5.0 75.5 91.8
DeKalb County 9,600 3.3 9,000 10,300 8,154 84.6 3.3 79.5 90.5
Fulton County 16,800 2.5 16,000 17,600 14,302 85.1 2.5 81.2 89.5
Gwinnett County 3,300 4.8 3,000 3,700 2,736 81.8 4.8 74.8 90.3
Illinois
Cook County 28,700 2.1 27,600 29,900 24,745 86.1 2.1 82.8 89.8
Indiana
Marion County 5,300 4.4 4,900 5,800 4,494 84.5 4.5 77.7 92.5
Louisiana
East Baton Rouge Parish 4,500 5.0 4,000 4,900 3,794 84.7 5.1 77.0 93.9
Orleans Parish 5,500 5.1 4,900 6,000 4,767 87.4 5.2 79.4 97.2
Maryland
Baltimore City 12,000 3.4 11,200 12,700 10,869 90.9 3.4 85.3 97.4
Montgomery County 4,300 5.0 3,900 4,700 3,772 87.9 5.1 80.0 97.4
Prince George’s County 8,800 3.4 8,200 9,400 7,529 85.6 3.4 80.2 91.7
Massachusetts
Suffolk Countyb 6,300 4.3 5,700 6,800 5,702 91.2 4.3 84.1 99.6
Michigan
Wayne County 7,500 4.3 6,900 8,200 6,370 84.4 4.3 77.9 92.1
Nevada
Clark Countyb 9,900 3.2 9,300 10,600 7,982 80.4 3.2 75.6 85.9
New Jersey
Essex Countyc 10,000 4.0 9,200 10,800 8,944 89.7 4.0 83.2 97.3
Hudson Countyc 5,500 5.2 4,900 6,100 4,797 87.0 5.3 78.9 96.9
New York
Bronx County 28,400 1.8 27,400 29,400 26,604 93.7 1.8 90.4 97.1
Kings County 27,800 2.0 26,700 29,000 25,708 92.3 2.1 88.7 96.2
New York County 28,600 2.1 27,400 29,800 26,747 93.6 2.2 89.8 97.7
Queens County 17,000 2.6 16,100 17,800 15,384 90.6 2.6 86.3 95.4
North Carolina
Mecklenburg County 6,500 3.9 6,000 7,000 5,623 86.8 3.9 80.6 94.0
Ohio
Cuyahoga County 5,400 4.4 4,900 5,900 4,585 84.7 4.5 77.9 92.7
Franklin County 5,600 4.3 5,100 6,100 4,742 84.8 4.4 78.2 92.6
Hamilton County 3,600 5.5 3,200 4,000 2,875 79.7 5.5 72.0 89.3
Pennsylvania
Philadelphia County 18,300 2.4 17,500 19,200 16,805 91.6 2.4 87.5 96.2
Puerto Rico
San Juan Municipioc 3,600 7.4 3,200 4,100 3,206 88.9 6.4 77.6 100
Tennessee
Shelby County 7,000 4.1 6,500 7,600 6,019 85.5 4.1 79.1 93.0
Texas
Bexar County 7,400 3.8 6,800 7,900 6,084 82.4 3.9 76.7 89.2
Dallas County 20,700 2.3 19,700 21,600 17,306 83.7 2.3 80.1 87.7
Harris County 29,700 2.0 28,500 30,800 24,655 83.1 2.0 80.0 86.5
Tarrant County 6,500 4.0 6,000 7,100 5,425 82.9 4.0 76.9 89.9
Travis County 5,700 4.4 5,200 6,200 4,712 82.5 4.4 75.9 90.2
Washington
King County 7,700 3.8 7,200 8,300 6,764 87.3 3.9 81.2 94.4
Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions
2018
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Arizona
Maricopa County 13,400 2.9 12,600 14,200 11,195 83.5 2.9 78.9 88.6
California
Alameda County 6,900 4.1 6,300 7,400 6,008 87.4 4.2 80.8 95.1
Los Angeles County 54,600 1.5 53,000 56,100 48,674 89.2 1.5 86.7 91.9
Orange County 8,200 3.9 7,600 8,800 6,845 83.7 3.9 77.8 90.6
Riverside County 10,100 2.7 9,500 10,600 9,041 89.7 2.7 85.2 94.8
Sacramento County 5,000 4.6 4,500 5,400 4,263 85.6 4.7 78.5 94.1
San Bernardino County 5,400 4.6 4,900 5,900 4,422 81.4 4.6 74.7 89.4
San Diego County 15,300 2.7 14,500 16,100 13,075 85.3 2.7 81.0 90.0
San Francisco County 12,700 3.6 12,100 13,600 12,115 95.3 2.9 89.1 100
District of Columbia 14,900 2.8 14,100 15,700 13,940 93.6 2.9 88.7 99.1
Florida
Broward County 21,800 2.2 20,800 22,700 19,274 88.5 2.2 84.8 92.6
Duval County 7,200 4.1 6,700 7,800 6,018 83.2 4.1 77.0 90.4
Hillsborough County 7,900 3.9 7,300 8,500 6,728 85.2 3.9 79.1 92.2
Miami-Dade County 30,100 2.1 28,800 31,300 26,015 86.5 2.1 83.1 90.3
Orange County 10,200 3.4 9,500 10,900 8,551 84.0 3.4 78.7 90.0
Palm Beach County 8,900 3.8 8,200 9,600 7,790 87.4 3.8 81.4 94.5
Pinellas County 5,100 4.6 4,700 5,600 4,482 87.1 4.6 79.9 95.7
Georgia
Cobb County 3,800 5.1 3,400 4,100 3,144 83.5 5.1 75.9 92.7
DeKalb County 10,000 3.3 9,300 10,600 8,456 84.8 3.4 79.6 90.8
Fulton County 17,600 2.5 16,700 18,500 15,072 85.7 2.5 81.7 90.1
Gwinnett County 3,500 5.0 3,100 3,800 2,852 82.6 5.1 75.2 91.6
Illinois
Cook County 28,900 2.1 27,700 30,100 25,050 86.6 2.1 83.1 90.3
Indiana
Marion County 5,500 4.5 5,000 6,000 4,618 84.1 4.6 77.2 92.3
Louisiana
East Baton Rouge Parish 4,600 5.2 4,100 5,000 3,857 84.5 5.2 76.7 94.1
Orleans Parish 5,500 5.2 5,000 6,100 4,859 87.9 5.3 79.7 97.9
Maryland
Baltimore City 11,100 3.7 10,300 11,900 10,073 90.5 3.7 84.3 97.5
Montgomery County 4,300 5.1 3,900 4,700 3,822 88.7 5.2 80.6 98.6
Prince George’s County 9,000 3.5 8,400 9,600 7,797 86.4 3.5 80.9 92.7
Massachusetts
Suffolk Countyb 6,200 4.4 5,700 6,700 5,654 91.2 4.5 83.9 99.9
Michigan
Wayne County 7,800 4.3 7,200 8,500 6,676 85.3 4.3 78.7 93.1
Nevada
Clark Countyb 10,600 3.3 9,900 11,300 8,522 80.6 3.3 75.7 86.2
New Jersey
Essex Countyc 9,900 4.1 9,100 10,700 8,914 90.0 4.1 83.2 97.8
Hudson Countyc 5,500 5.4 5,000 6,100 4,807 86.8 5.4 78.5 97.0
New York
Bronx County 28,600 1.8 27,500 29,600 26,805 93.8 1.8 90.6 97.3
Kings County 27,900 2.1 26,800 29,100 25,888 92.6 2.1 89.0 96.6
New York County 28,500 2.2 27,300 29,700 26,738 93.9 2.2 90.1 98.1
Queens County 17,100 2.6 16,200 17,900 15,600 91.3 2.6 86.9 96.2
North Carolina
Mecklenburg County 6,600 4.0 6,100 7,100 5,815 87.9 4.0 81.5 95.3
Ohio
Cuyahoga County 5,500 4.5 5,000 6,000 4,684 85.5 4.5 78.6 93.8
Franklin County 5,700 4.5 5,200 6,200 4,803 84.7 4.5 77.8 92.8
Hamilton County 3,600 5.8 3,200 4,000 2,906 80.6 5.9 72.4 91.0
Pennsylvania
Philadelphia County 18,200 2.5 17,400 19,100 16,757 91.8 2.5 87.6 96.5
Puerto Rico
San Juan Municipioc 3,600 7.5 3,200 4,100 3,247 90.0 6.1 78.5 100
Tennessee
Shelby County 7,200 4.1 6,600 7,800 6,273 86.8 4.1 80.3 94.4
Texas
Bexar County 7,600 4.0 7,000 8,200 6,268 82.7 4.0 76.8 89.7
Dallas County 21,400 2.3 20,400 22,400 17,992 84.1 2.3 80.5 88.2
Harris County 30,500 2.0 29,200 31,700 25,469 83.6 2.0 80.5 87.1
Tarrant County 6,800 4.1 6,200 7,300 5,647 83.5 4.1 77.4 90.7
Travis County 5,900 4.4 5,400 6,500 4,892 82.2 4.5 75.6 90.1
Washington
King County 7,800 4.0 7,200 8,400 6,828 87.4 4.0 81.1 94.8
Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions
2019
Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
Area of residence No. RSE 95% CI No.a % RSE 95% CI
Arizona
Maricopa County 13,900 3.0 13,100 14,700 11,691 84.0 3.0 79.3 89.3
California
Alameda County 6,900 4.3 6,300 7,500 6,058 87.7 4.3 80.9 95.8
Los Angeles County 55,100 1.5 53,500 56,700 49,404 89.6 1.5 87.1 92.4
Orange County 8,200 4.0 7,600 8,900 6,941 84.3 4.0 78.2 91.4
Riverside County 10,400 2.8 9,900 11,000 9,414 90.2 2.8 85.5 95.4
Sacramento County 5,100 4.8 4,600 5,500 4,336 85.7 4.8 78.4 94.5
San Bernardino County 5,700 4.7 5,200 6,200 4,690 82.1 4.8 75.2 90.5
San Diego County 15,400 2.8 14,600 16,300 13,173 85.4 2.8 81.0 90.4
San Francisco County 12,500 3.7 12,000 13,400 11,992 95.9 2.8 89.5 100
District of Columbia 14,800 2.9 14,000 15,600 13,913 94.0 2.9 88.9 99.7
Florida
Broward County 22,100 2.3 21,100 23,100 19,594 88.8 2.3 85.0 93.0
Duval County 7,300 4.2 6,700 7,900 6,159 84.4 4.2 78.0 92.0
Hillsborough County 8,100 3.9 7,400 8,700 6,948 86.1 4.0 80.0 93.4
Miami-Dade County 30,300 2.2 29,000 31,600 26,296 86.8 2.2 83.2 90.7
Orange County 10,400 3.5 9,700 11,100 8,770 84.4 3.6 78.9 90.7
Palm Beach County 9,000 3.9 8,300 9,700 7,890 87.6 3.9 81.5 94.8
Pinellas County 5,300 4.6 4,800 5,800 4,666 88.1 4.7 80.7 97.0
Georgia
Cobb County 4,000 5.3 3,600 4,400 3,314 83.4 5.4 75.5 93.1
DeKalb County 10,300 3.4 9,600 11,000 8,815 85.5 3.4 80.2 91.6
Fulton County 18,100 2.5 17,200 19,000 15,584 86.2 2.6 82.1 90.8
Gwinnett County 3,600 5.4 3,200 4,000 3,033 83.6 5.4 75.6 93.4
Illinois
Cook County 29,500 2.2 28,200 30,800 25,619 86.9 2.2 83.3 90.7
Indiana
Marion County 5,500 4.8 5,000 6,000 4,610 83.5 4.9 76.2 92.3
Louisiana
East Baton Rouge Parish 4,600 5.4 4,100 5,100 3,898 84.2 5.4 76.2 94.1
Orleans Parish 5,600 5.3 5,000 6,200 4,957 88.3 5.3 80.1 98.5
Maryland
Baltimore City 11,100 3.8 10,300 11,900 10,109 91.0 3.8 84.7 98.2
Montgomery County 4,300 5.3 3,900 4,800 3,867 89.7 5.3 81.3 100.0
Prince George’s County 9,100 3.6 8,500 9,800 7,947 86.9 3.6 81.3 93.5
Massachusetts
Suffolk Countyb 6,200 4.5 5,700 6,800 5,695 91.2 4.5 83.8 100.0
Michigan
Wayne County 8,000 4.3 7,400 8,700 6,889 85.6 4.4 78.9 93.5
Nevada
Clark Countyb 11,200 3.5 10,400 12,000 8,976 80.1 3.5 74.9 85.9
New Jersey
Essex Countyc 9,900 4.2 9,100 10,700 8,937 90.2 4.3 83.3 98.3
Hudson Countyc 5,600 5.5 5,000 6,200 4,845 87.3 5.6 78.7 97.8
New York
Bronx County 29,000 1.9 27,900 30,000 27,307 94.3 1.9 91.0 97.8
Kings County 27,900 2.1 26,800 29,100 25,949 93.0 2.1 89.2 97.0
New York County 28,300 2.2 27,100 29,500 26,649 94.1 2.2 90.2 98.4
Queens County 17,200 2.6 16,300 18,100 15,836 92.2 2.6 87.7 97.2
North Carolina
Mecklenburg County 6,800 4.1 6,300 7,300 6,045 88.8 4.1 82.3 96.5
Ohio
Cuyahoga County 5,500 4.6 5,000 6,000 4,758 86.2 4.7 79.0 94.9
Franklin County 5,900 4.6 5,400 6,400 5,013 85.2 4.6 78.2 93.6
Hamilton County 3,700 6.0 3,300 4,100 3,037 82.4 6.0 73.8 93.3
Pennsylvania
Philadelphia County 18,400 2.5 17,500 19,300 16,951 92.2 2.5 87.8 97.0
Puerto Rico
San Juan Municipioc 3,600 7.5 3,300 4,200 3,309 90.8 5.9 79.1 100
Tennessee
Shelby County 7,200 4.3 6,600 7,800 6,256 87.2 4.3 80.4 95.1
Texas
Bexar County 7,900 4.1 7,300 8,500 6,538 82.9 4.1 76.7 90.2
Dallas County 21,900 2.4 20,900 22,900 18,648 85.1 2.4 81.3 89.3
Harris County 27,300 2.4 26,000 28,500 22,267 81.6 2.4 78.0 85.7
Tarrant County 7,100 4.2 6,500 7,600 5,909 83.8 4.2 77.4 91.3
Travis County 6,100 4.5 5,600 6,600 5,028 82.5 4.6 75.7 90.5
Washington
King County 8,000 4.1 7,400 8,600 7,015 87.7 4.1 81.2 95.4

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage (footnotes only).
Note. Estimates for the year 2019 data are preliminary and based on deaths reported to CDC as of December 2020. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates >1,000 and to the nearest 10 for estimates ≤1,000 to reflect the uncertainty.

aReported to the National HIV Surveillance System.
bEstimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.
cEstimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: New Jersey. Areas with incomplete reporting: Pennsylvania (excluding Philadelphia County) and Puerto Rico.

Table 3a. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, 2017–2020—50 states and the District of Columbia
2017 2018 2019 2020
(preliminary)a
No. No. No. No.
Gender
Male 30,411 29,699 28,781 19,956
Female 7,248 7,025 6,868 4,517
Transgender male-to-femaleb 581 596 623 439
Transgender female-to-maleb 36 48 46 38
Additional gender identityc 13 14 19 10
Age at diagnosis (yr)
13–24 8,281 7,835 7,588 4,970
25–34 13,361 13,382 13,014 9,140
35–44 7,241 7,181 7,068 4,881
45–54 5,569 5,233 4,866 3,308
≥55 3,837 3,751 3,801 2,661
Race/ethnicity
American Indian/Alaska Native 206 182 209 163
Asian 915 849 732 513
Black/African American 15,931 15,441 15,299 10,983
Hispanic/Latinod 10,460 10,530 10,112 6,135
Native Hawaiian/other Pacific Islander 51 64 66 57
White 9,546 9,293 9,006 6,642
Multiracial 1,180 1,023 913 467
Transmission categorye
Male-to-male sexual contact 25,337 24,556 23,866 16,964
Injection drug use
      Male 1,301 1,407 1,375 963
      Female 1,053 1,084 1,106 674
Male-to-male sexual contact and injection drug use 1,421 1,408 1,457 833
Heterosexual contactf
      Male 2,913 2,903 2,685 1,620
      Female 6,198 5,958 5,787 3,860
Otherg
      Male 34 35 37 25
      Female 33 32 25 21
Region of residenceh
Northeast 6,000 5,562 5,268 3,356
Midwest 5,086 4,932 4,750 3,417
South 19,658 19,364 19,100 13,291
West 7,545 7,524 7,219 4,896
Total 38,289 37,382 36,337 24,960

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
bTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.” dHispanic/Latino persons can be of any race.
eData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection. gIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
hData are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, 2017–2020—United States and 6 dependent areas
2017 2018 2019 2020
(preliminary)a
No. No. No. No.
Gender
Male 30,780 30,066 29,101 20,169
Female 7,342 7,106 6,949 4,554
Transgender male-to-femaleb 583 597 625 440
Transgender female-to-maleb 36 48 46 38
Additional gender identityc 13 14 19 10
Age at diagnosis (yr)
13–24 8,359 7,909 7,648 5,015
25–34 13,490 13,517 13,127 9,209
35–44 7,331 7,259 7,147 4,932
45–54 5,662 5,327 4,931 3,349
≥55 3,912 3,819 3,887 2,706
Race/ethnicity
American Indian/Alaska Native 206 182 209 163
Asian 918 853 738 513
Black/African American 15,935 15,448 15,305 10,985
Hispanic/Latinod 10,910 10,960 10,494 6,382
Native Hawaiian/other Pacific Islander 54 66 70 57
White 9,550 9,297 9,011 6,644
Multiracial 1,181 1,025 913 467
Transmission categorye
Male-to-male sexual contact 25,580 24,819 24,084 17,118
Injection drug use
      Male 1,333 1,432 1,397 985
      Female 1,062 1,086 1,111 676
Male-to-male sexual contact and injection drug use 1,432 1,420 1,468 839
Heterosexual contactf
      Male 2,997 2,970 2,754 1,653
      Female 6,283 6,037 5,863 3,894
Otherg
      Male 34 35 37 25
      Female 33 32 25 21
Region of residenceh
Northeast 6,000 5,562 5,268 3,356
Midwest 5,086 4,932 4,750 3,417
South 19,658 19,364 19,100 13,291
West 7,545 7,524 7,219 4,896
U.S. dependent areas 465 449 403 251
Total 38,754 37,831 36,740 25,211

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
bTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dHispanic/Latino persons can be of any race.
eData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
hData are based on residence at time of diagnosis of HIV infection.

Table 3c. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, 2017–2020—United States and 6 dependent areas
2017 2018 2019 2020
(preliminary)a
No. No. No. No.
Alabama 650 607 638 514
Alaska 29 23 27 29
Arizona 727 753 761 605
Arkansas 287 278 287 253
California 4,806 4,715 4,354 2,828
Colorado 435 402 461 295
Connecticut 274 259 213 147
Delaware 126 91 93 94
District of Columbia 316 281 255 184
Florida 4,557 4,530 4,378 3,468
Georgia 2,596 2,482 2,439 1,583
Hawaii 77 72 65 38
Idaho 46 37 28 9
Illinois 1,367 1,374 1,252 681
Indiana 515 509 486 398
Iowa 125 116 100 90
Kansas 119 157 131 103
Kentucky 365 378 326 242
Louisiana 996 961 881 729
Maine 29 30 30 16
Maryland 1,020 991 918 591
Massachusetts 608 649 535 305
Michigan 773 715 674 511
Minnesota 277 288 274 210
Mississippi 428 476 477 341
Missouri 502 449 488 348
Montana 32 23 25 14
Nebraska 88 79 81 56
Nevada 494 501 512 297
New Hampshire 32 38 31 29
New Jersey 1,123 1,021 1,057 525
New Mexico 141 135 156 51
New York 2,729 2,449 2,330 1,593
North Carolina 1,295 1,186 1,365 1,026
North Dakota 38 36 40 11
Ohio 983 973 980 789
Oklahoma 299 278 320 194
Oregon 203 230 199 169
Pennsylvania 1,100 1,023 989 687
Rhode Island 85 75 72 47
South Carolina 706 712 680 656
South Dakota 39 29 33 32
Tennessee 721 746 773 614
Texas 4,356 4,422 4,302 2,095
Utah 113 121 135 126
Vermont 20 18 11 7
Virginia 863 861 822 594
Washington 432 500 483 423
West Virginia 77 84 146 113
Wisconsin 260 207 211 188
Wyoming 10 12 13 12
Subtotal 38,289 37,382 36,337 24,960
U.S. dependent areas
American Samoa 0 0 0 0
Guam 6 7 10 0
Northern Mariana Islands 1 1 2 0
Puerto Rico 450 431 383 249
Republic of Palau 0 0 0 0
U.S. Virgin Islands 8 10 8 2
Subtotal 465 449 403 251
Total 38,754 37,831 36,740 25,211

Note. Data are based on residence at time of diagnosis of HIV infection.

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 3d. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, 2017–2020—Ending the HIV Epidemic Phase I jurisdictions
2017 2018 2019 2020
(preliminary)a
No. No. No. No.
Arizona
Maricopa County 497 530 513 442
California
Alameda County 203 199 219 137
Los Angeles County 1,725 1,685 1,482 931
Orange County 313 287 246 246
Riverside County 276 262 268 214
Sacramento County 170 156 136 20
San Bernardino County 254 263 287 179
San Diego County 414 382 366 196
San Francisco County 243 238 207 149
District of Columbia 316 281 255 184
Florida
Broward County 671 616 594 479
Duval County 297 275 273 222
Hillsborough County 300 299 266 259
Miami-Dade County 1,145 1,168 1,151 826
Orange County 461 461 466 372
Palm Beach County 289 280 237 215
Pinellas County 163 175 184 151
Georgia
Cobb County 156 153 179 112
DeKalb County 366 355 351 218
Fulton County 615 592 537 440
Gwinnett County 178 148 208 93
Illinois
Cook County 979 983 881 531
Indiana
Marion County 227 204 206 146
Louisiana
East Baton Rouge Parish 163 177 153 119
Orleans Parish 184 179 158 104
Maryland
Baltimore City 236 231 199 141
Montgomery County 164 126 132 73
Prince George’s County 308 306 279 165
Massachusetts
Suffolk County 165 149 133 99
Michigan
Wayne County 323 300 285 218
Nevada
Clark County 445 445 449 255
New Jersey
Essex County 315 265 234 127
Hudson County 164 161 147 93
New York
Bronx County 505 456 499 271
Kings County 628 547 466 348
New York County 394 374 338 247
Queens County 431 413 354 251
North Carolina
Mecklenburg County 270 242 267 201
Ohio
Cuyahoga County 148 149 162 171
Franklin County 222 194 214 171
Hamilton County 187 183 173 117
Pennsylvania
Philadelphia County 506 439 446 278
Puerto Rico
San Juan Municipio 112 106 85 57
Tennessee
Shelby County 260 291 263 224
Texas
Bexar County 349 325 336 216
Dallas County 813 794 733 526
Harris County 1,102 1,206 1,195 339
Tarrant County 304 277 307 185
Travis County 212 188 174 111
Washington
King County 211 292 245 214

Note. Data are based on residence at time of diagnosis of HIV infection.

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2019–September 2020—44 states and the District of Columbia
2019 2020 (January–September, preliminary)a
Total ≥1 CD4 or VL tests No CD4 or VL test Total ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. % No. No. % No. %
Gender
Male 26,827 21,873 81.5 4,954 18.5 15,460 12,774 82.6 2,686 17.4
Female 6,322 5,067 80.1 1,255 19.9 3,549 2,928 82.5 621 17.5
Transgender male-to-femaleb 584 484 82.9 100 17.1 349 292 83.7 57 16.3
Transgender female-to-maleb 45 40 88.9 5 11.1 28 27 96.4 1 3.6
Additional gender identityc 17 15 88.2 2 11.8 7 7 100 0 0.0
Age at diagnosis (yr)
13–24 7,093 5,602 79.0 1,491 21.0 3,895 3,133 80.4 762 19.6
25–34 12,105 9,775 80.8 2,330 19.2 7,160 5,896 82.3 1,264 17.7
35–44 6,560 5,405 82.4 1,155 17.6 3,719 3,067 82.5 652 17.5
45–54 4,523 3,767 83.3 756 16.7 2,542 2,167 85.2 375 14.8
≥55 3,514 2,930 83.4 584 16.6 2,077 1,765 85.0 312 15.0
Race/ethnicity
American Indian/Alaska Native 206 172 83.5 34 16.5 127 103 81.1 24 18.9
Asian 687 570 83.0 117 17.0 409 366 89.5 43 10.5
Black/African American 14,268 11,179 78.4 3,089 21.6 8,510 6,870 80.7 1,640 19.3
Hispanic/Latinod 9,478 8,004 84.4 1,474 15.6 4,902 4,111 83.9 791 16.1
Native Hawaiian/other Pacific Islander 66 53 80.3 13 19.7 49 41 83.7 8 16.3
White 8,249 6,817 82.6 1,432 17.4 5,028 4,217 83.9 811 16.1
Multiracial 841 684 81.3 157 18.7 368 320 87.0 48 13.0
Transmission categorye
Male-to-male sexual contact 22,392 18,389 82.1 4,003 17.9 13,203 10,955 83.0 2,247 17.0
Injection drug use 1,190 900 75.7 290 24.3 694 556 80.2 137 19.8
      Male 985 740 75.1 245 24.9 538 429 79.7 109 20.3
      Female 1,347 1,080 80.2 267 19.8 650 531 81.7 119 18.3
Male-to-male sexual contact and injection drug use 2,459 1,969 80.1 490 19.9 1,251 1,014 81.1 237 18.9
Heterosexual contactf 5,362 4,351 81.1 1,011 18.9 3,020 2,509 83.1 512 16.9
      Male 36 31 85.6 5 14.4 18 16 87.6 2 12.4
      Female 24 20 80.9 5 19.1 19 18 93.2 1 6.8
Totalg 33,795 27,479 81.3 6,316 18.7 19,393 16,028 82.6 3,365 17.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis.
Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
bTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dHispanic/Latino persons can be of any race.
eData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 4b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—44 states and the District of Columbia
2019 2020 (January–September, preliminary)a
Total ≥1 CD4 or VL tests No CD4 or VL test Total ≥1 CD4 or VL tests No CD4 or VL test
Area of residence No. No. % No. % No. No. % No. %
Alabama 638 505 79.2 133 20.8 432 335 77.5 97 22.5
Alaska 27 23 85.2 4 14.8 24 23 95.8 1 4.2
Arizona 761 630 82.8 131 17.2 504 427 84.7 77 15.3
Arkansas 287 229 79.8 58 20.2 211 176 83.4 35 16.6
California 4,354 3,601 82.7 753 17.3 2,424 2,063 85.1 361 14.9
Colorado 461 385 83.5 76 16.5 232 201 86.6 31 13.4
Connecticut 213 186 87.3 27 12.7 133 111 83.5 22 16.5
Delaware 93 71 76.3 22 23.7 73 58 79.5 15 20.5
District of Columbia 255 210 82.4 45 17.6 144 130 90.3 14 9.7
Florida 4,378 3,662 83.6 716 16.4 2,677 2,258 84.3 419 15.7
Georgia 2,439 1,961 80.4 478 19.6 1,330 1,148 86.3 182 13.7
Hawaii 65 55 84.6 10 15.4 28 25 89.3 3 10.7
Illinois 1,252 1,042 83.2 210 16.8 621 532 85.7 89 14.3
Indiana 486 307 63.2 179 36.8 320 232 72.5 88 27.5
Iowa 100 91 91.0 9 9.0 70 63 90.0 7 10.0
Louisiana 881 722 82.0 159 18.0 543 408 75.1 135 24.9
Maine 30 28 93.3 2 6.7 13 12 92.3 1 7.7
Maryland 918 798 86.9 120 13.1 507 460 90.7 47 9.3
Massachusetts 535 486 90.8 49 9.2 276 240 87.0 36 13.0
Michigan 674 565 83.8 109 16.2 392 327 83.4 65 16.6
Minnesota 274 250 91.2 24 8.8 162 141 87.0 21 13.0
Mississippi 477 339 71.1 138 28.9 282 215 76.2 67 23.8
Missouri 488 376 77.0 112 23.0 273 213 78.0 60 22.0
Montana 25 22 88.0 3 12.0 8 7 87.5 1 12.5
Nebraska 81 65 80.2 16 19.8 44 41 93.2 3 6.8
Nevada 512 425 83.0 87 17.0             257 222 86.4 35 13.6
New Hampshire 31 27 87.1 4 12.9                22 17 77.3 5 22.7
New Mexico 156 138 88.5 18 11.5                47 41 87.2 6 12.8
New York 2,330 2,027 87.0 303 13.0          1,399 1,226 87.6 173 12.4
North Carolina 1,365 1,077 78.9 288 21.1 802 665 82.9 137 17.1
North Dakota 40 36 90.0 4 10.0 11 10 90.9 1 9.1
Ohio 980 819 83.6 161 16.4 690 607 88.0 83 12.0
Oklahoma 320 222 69.4 98 30.6 156 122 78.2 34 21.8
Oregon 199 173 86.9 26 13.1 131 113 86.3 18 13.7
Rhode Island 72 65 90.3 7 9.7 44 41 93.2 3 6.8
South Carolina 680 596 87.6 84 12.4 529 467 88.3 62 11.7
South Dakota 33 26 78.8 7 21.2 27 23 85.2 4 14.8
Tennessee 773 534 69.1 239 30.9 497 370 74.4 127 25.6
Texas 4,302 3,210 74.6 1,092 25.4 1,911 1,331 69.6 580 30.4
Utah 135 106 78.5 29 21.5 103 46 44.7 57 55.3
Virginia 822 647 78.7 175 21.3 474 380 80.2 94 19.8
Washington 483 432 89.4 51 10.6 319 287 90.0 32 10.0
West Virginia 146 107 73.3 39 26.7 101 78 77.2 23 22.8
Wisconsin 211 190 90.0 21 10.0 141 128 90.8 13 9.2
Wyoming 13 13 100 0 0.0 9 8 88.9 1 11.1
Total 33,795 27,479 81.3 6,316 18.7 19,393 16,028 82.6 3,365 17.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico , and Vermont.

aData are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 4c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—Ending the HIV Epidemic Phase I jurisdictions
2019 2020 (January–September, preliminary)a
Total ≥1 CD4 or VL tests No CD4 or VL test Total ≥1 CD4 or VL tests No CD4 or VL test
No. No. % No. % No. No. % No. %
Arizona
Maricopa County 513 417 81.3 96 18.7 364 312 85.7 52 14.3
California
Alameda County 219 195 89.0 24 11.0 117 98 83.8 19 16.2
Los Angeles County 1,482 1,198 80.8 284 19.2 806 688 85.4 118 14.6
Orange County 246 199 80.9 47 19.1 201 180 89.6 21 10.4
Riverside County 268 216 80.6 52 19.4 176 145 82.4 31 17.6
Sacramento County 136 118 86.8 18 13.2 15 11 73.3 4 26.7
San Bernardino County 287 208 72.5 79 27.5 166 123 74.1 43 25.9
San Diego County 366 317 86.6 49 13.4 191 170 89.0 21 11.0
San Francisco County 207 199 96.1 8 3.9 116 111 95.7 5 4.3
District of Columbia 255 210 82.4 45 17.6 144 130 90.3 14 9.7
Florida
Broward County 594 517 87.0 77 13.0 359 310 86.4 49 13.6
Duval County 273 210 76.9 63 23.1 178 143 80.3 35 19.7
Hillsborough County 266 228 85.7 38 14.3 196 167 85.2 29 14.8
Miami-Dade County 1,151 971 84.4 180 15.6 641 533 83.2 108 16.8
Orange County 466 365 78.3 101 21.7 289 251 86.9 38 13.1
Palm Beach County 237 187 78.9 50 21.1 179 148 82.7 31 17.3
Pinellas County 184 157 85.3 27 14.7 116 101 87.1 15 12.9
Georgia
Cobb County 179 151 84.4 28 15.6 87 78 89.7 9 10.3
DeKalb County 351 284 80.9 67 19.1 186 164 88.2 22 11.8
Fulton County 537 450 83.8 87 16.2 356 311 87.4 45 12.6
Gwinnett County 208 170 81.7 38 18.3 84 67 79.8 17 20.2
Illinois
Cook County 881 732 83.1 149 16.9 479 410 85.6 69 14.4
Indiana
Marion County 206 108 52.4 98 47.6 126 90 71.4 36 28.6
Louisiana
East Baton Rouge Parish 153 135 88.2 18 11.8 95 75 78.9 20 21.1
Orleans Parish 158 130 82.3 28 17.7 72 57 79.2 15 20.8
Maryland
Baltimore City 199 169 84.9 30 15.1 124 111 89.5 13 10.5
Montgomery County 132 117 88.6 15 11.4 60 57 95.0 3 5.0
Prince George’s County 279 245 87.8 34 12.2 150 137 91.3 13 8.7
Massachusetts
Suffolk County 133 124 93.2 9 6.8 85 74 87.1 11 12.9
Michigan
Wayne County 285 243 85.3 42 14.7 168 138 82.1 30 17.9
Nevada
   Clark County 449 371 82.6 78 17.4 222 191 86.0 31 14.0
New York
Bronx County 499 435 87.2 64 12.8 241 208 86.3 33 13.7
Kings County 466 397 85.2 69 14.8 306 265 86.6 41 13.4
New York County 338 297 87.9 41 12.1 214 179 83.6 35 16.4
Queens County 354 302 85.3 52 14.7 229 212 92.6 17 7.4
North Carolina
Mecklenburg County 267 209 78.3 58 21.7 148 122 82.4 26 17.6
Ohio
Cuyahoga County 162 143 88.3 19 11.7 141 131 92.9 10 7.1
Franklin County 214 196 91.6 18 8.4 153 137 89.5 16 10.5
Hamilton County 173 147 85.0 26 15.0 102 92 90.2 10 9.8
Pennsylvania
Philadelphia County 446 377 84.5 69 15.5 223 193 86.5 30 13.5
Tennessee
Shelby County 263 160 60.8 103 39.2 185 128 69.2 57 30.8
Texas
Bexar County 336 237 70.5 99 29.5 208 132 63.5 76 36.5
Dallas County 733 557 76.0 176 24.0 462 319 69.0 143 31.0
Harris County 1,195 889 74.4 306 25.6 335 233 69.6 102 30.4
Tarrant County 307 218 71.0 89 29.0 158 103 65.2 55 34.8
Travis County 174 152 87.4 22 12.6 99 77 77.8 22 22.2
Washington
King County 245 222 90.6 23 9.4 151 140 92.7 11 7.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey. Areas with incomplete reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

Table 5a. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by selected characteristics—44 states and the District of Columbia
Persons alive at year-end 2019 VL < 200 copies/mL
No. No. %
Gender
Male 702,412 462,753 65.9
Female 212,405 136,113 64.1
Transgender male-to-femalea 9,699 6,503 67.0
Transgender female-to-malea 391 267 68.3
Additional gender identityb 170 120 70.6
Age at year-end 2018 (yr)
13–24 29,533 18,681 63.3
25–34 147,061 91,988 62.6
35–44 175,204 110,891 63.3
45–54 254,886 169,826 66.6
≥55 318,393 214,370 67.3
Race/ethnicity
American Indian/Alaska Native 2,924 1,836 62.8
Asianc 13,903 9,731 70.0
Black/African American 371,711    225,899 60.8
Hispanic/Latinod 220,914 142,709 64.6
Native Hawaiian/other Pacific Islander 815 529 64.9
White 270,980 193,402 71.4
Multiracial 43,145 31,592 73.2
Transmission categorye
Male-to-male sexual contact 528,606 359,821 68.1
Injection drug use
      Male 56813 30489 53.7
      Female Injection drug use 41,478 25,418 61.3
Male-to-male sexual contact and injection drug use 51,307 33,657 65.6
Heterosexual contactf
      Male 68,761 41,608 60.5
      Female 164787 107234 65.1
Otherg
     Male 6,771 3,787 55.9
     Female 6,554 3,742 57.1
Totalh 925,077 605,756 65.5

Abbreviation: VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

aTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cIncludes Asian/Pacific Islander legacy cases.
dHispanic/Latino persons can be of any race.
eData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column total. Data presented based on sex at birth and include transgender persons.
fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
hIncludes 685 persons of unknown race/ethnicity.

Table 5b. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence— 44 states and the District of Columbia
Persons alive at year-end 2019 VL < 200 copies/mL
Area of residence No. No. %
Alabama 13,245 8,837 66.7
Alaska 700 552 78.9
Arizona 16,537 10,276 62.1
Arkansas 5,668 2,715 47.9
California 128,592 86,913 67.6
Colorado 12,556 7,526 59.9
Connecticut 10,380 7,059 68.0
Delaware 3,286 2,456 74.7
District of Columbia 13,777 8,082 58.7
Florida 109,195 73,187 67.0
Georgia 54,031 33,270 61.6
Hawaii 2,324 1,762 75.8
Illinois 34,564 19,097 55.3
Indiana 11,145 6,705 60.2
Iowa 2,785 2,275 81.7
Louisiana 20,425 13,952 68.3
Maine 1,613 1,307 81.0
Maryland 32,466 21,083 64.9
Massachusettsa 20,514 14,581 71.1
Michigan 15,903 11,713 73.7
Minnesota 8,532 5,934 69.5
Mississippia 9,356 5,043 53.9
Missouri 12,320 8,277 67.2
Montana 638 535 83.9
Nebraska 2,151 1,355 63.0
Nevadaa 10,228 5,911 57.8
New Hampshire 1,273 965 75.8
New Mexico 3,582 2,162 60.4
New York 124,135 81,751 65.9
North Carolina 31,640 21,291 67.3
North Dakotaa 456 324 71.1
Ohio 22,204 13,969 62.9
Oklahoma 6,033 3,521 58.4
Oregon 7,080 5,701 80.5
Rhode Island 2,584 2,047 79.2
South Carolina 16,917 11,967 70.7
South Dakota 618 321 51.9
Tennessee 16,957 11,383 67.1
Texas 90,852 56,315 62.0
Utah 2,947 2,092 71.0
Virginia 22,870 14,462 63.2
Washington 13,539 10,861 80.2
West Virginia 1,847 1,182 64.0
Wisconsin 6,279 4,813 76.7
Wyoming 333 226 67.9

Abbreviations: VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

aEstimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 5c. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence — Ending the HIV Epidemic Phase I jurisdictions
Persons alive at year-end 2019 VL < 200 copies/mL
Area of residence No. No. %
Arizona
Maricopa County 11,288 7,262 64.3
California
Alameda County 5,886 4,311 73.2
Los Angeles County 48,185 31,185 64.7
Orange County 6,744 4,438 65.8
Riverside County 9,196 7,198 78.3
Sacramento County 4,230 2,984 70.5
San Bernardino County 4,445 2,759 62.1
San Diego County 12,882 7,866 61.1
San Francisco County 11,804 9,086 77.0
District of Columbia 13,777 8,082 58.7
Florida
Broward County 19,237 13,416 69.7
Duval County 5,973 3,816 63.9
Hillsborough County 6,784 4,891 72.1
Miami-Dade County 25,480 15,194 59.6
Orange County 8,432 5,815 69.0
Palm Beach County 7,785 4,854 62.4
Pinellas County 4,521 3,437 76.0
Georgia
Cobb County 3,168 2,049 64.7
DeKalb County 8,528 5,504 64.5
Fulton County 15,116 9,378 62.0
Gwinnett County 2,885 1,921 66.6
Illinois
Cook County 24,960 13,074 52.4
Indiana
Marion County 4,450  2,611 58.7
Louisiana
East Baton Rouge Parish 3,795 2,775 73.1
Orleans Parish 4,833 3,294 68.2
Maryland
Baltimore City 10,091 6,409 63.5
Montgomery County 3,787 2,148 56.7
Prince George’s County 7,786 5,063 65.0
Massachusetts
Suffolk Countya 5,621 3,986 70.9
Michigan
Wayne County 6,666 4,652 69.8
Nevada
   Clark Countya 8,601 5,068 58.9
New York
Bronx County 27,548 18,158 65.9
Kings County 26,035 16,886 64.9
New York County 26,599 16,660 62.6
Queens County 15,730 10,124 64.4
North Carolina
Mecklenburg County 5,822 4,068 69.9
Ohio
Cuyahoga County 4,642 3,082 66.4
Franklin County 4,846 3,275 67.6
Hamilton County 2,884 1,406 48.8
Pennsylvania
Philadelphia County 16,731 10,656 63.7
Tennessee
Shelby County  6,079 3,957 65.1
Texas
Bexar County 6,246 4,088 65.4
Dallas County 17,992  10,980 61.0
Harris County 21,455 12,282 57.2
Tarrant County 5,678 3,695 65.1
Travis County 4,873 3,662 75.1
Washington
King County 6,844 5,673 82.9

Abbreviations:  VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

aEstimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 6a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2020, among persons aged ≥16 years, by selected characteristics—United States
Area of Residence 2017 2018 2019 2020 (January-September)
Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Sex at birth
Male 149,620 993,840 15.1 210,427 989,200 21.3 262,360 989,200 26.5 254,738 989,200 25.8
Female 11,458 227,240 5.0 15,995 227,010 7.0 21,955 227,010 9.7 20,430 227,010 9.0
Age (yr)
16-24 20,071 259,130 7.7 29,743 246,290 12.1 38,316 246,290 15.6 31,871 246,290 12.9
25-34 64,906 425,690 15.2 92,924 434,680 21.4 116,012 434,680 26.7 108,718 434,680 25.0
35-44 38,088 233,560 16.3 52,576 238,470 22.0 66,005 238,470 27.7 67,169 238,470 28.2
45-54 25,252 180,870 14.0 32,775 173,420 18.9 38,718 173,420 22.3 38,505 173,420 22.2
≥55 12,868 121,830 10.6 18,523 123,350 15.0 25,413 123,350 20.6 29,006 123,350 23.5
Race/ethnicityd
Black/African American 20,255 475,100 4.3 29,262 468,540 6.2 38,284 468,540 8.2 37,467 468,540 8.0
Hispanic/Latinoe 23,142 299,580 7.7 34,228 312,820 10.9 43,812 312,820 14.0 42,831 312,820 13.7
Other 7,149 132,040 5.4 9,836 131,180 7.5 11,953 131,180 9.1 11,201 131,180 8.5
White 110,638 311,250 35.5 153,215 300,650 51.0 190,415 300,650 63.3 183,769 300,650 61.1
Total 161,185 1,221,080 13.2 226,541 1,216,210 18.6 284,464 1,216,210 23.4 275,269 1,216,210 22.6

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2017 and 2018 data from National HIV Surveillance System, data from the National Health and Nutrition Examination Survey, and from U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dRace/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
eHispanic/Latino persons can be of any race.

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2020, among persons aged ≥16 years, by area of residence—United States and Puerto Rico
Area of Residence 2017 2018 2019 2020 (January-September)
Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Alabama 1,014 11,390 8.9 1,557 11,020 14.1 1,907 11,020 17.3 1,808 11,020 16.4
Alaska 120 2,370 5.1 196 1,780 11.0 236 1,780 13.3 221 1,780 12.4
Arizona 2,430 26,820 9.1 3,694 25,780 14.3 4,825 25,780 18.7 4,758 25,780 18.5
Arkansas 445 4,840 9.2 632 5,130 12.3 794 5,130 15.5 811 5,130 15.8
California 28,138 166,150 16.9 37,659 165,030 22.8 43,952 165,030 26.6 40,094 165,030 24.3
Colorado 2,484 25,510 9.7 3,517 25,120 14.0 4,434 25,120 17.7 4,293 25,120 17.1
Connecticut 1,636 10,970 14.9 2,349 9,560 24.6 2,805 9,560 29.3 2,306 9,560 24.1
Delaware 287 4,860 5.9 423 4,400 9.6 488 4,400 11.1 421 4,400 9.6
District of Columbia 4,018 13,710 29.3 5,212 12,950 40.2 6,077 12,950 46.9 5,684 12,950 43.9
Florida 8,731 125,160 7.0 14,999 125,330 12.0 22,439 125,330 17.9 30,104 125,330 24.0
Georgia 4,685 40,680 11.5 6,548 39,030 16.8 8,999 39,030 23.1 8,907 39,030 22.8
Hawaii 460 5,440 8.5 698 4,360 16.0 857 4,360 19.7 811 4,360 18.6
Idaho 272 3,860 7.0 380 4,790 7.9 487 4,790 10.2 579 4,790 12.1
Illinois 10,605 54,620 19.4 14,334 55,860 25.7 17,190 55,860 30.8 14,883 55,860 26.6
Indiana 1,577 21,640 7.3 2,251 22,170 10.2 3,097 22,170 14.0 2,849 22,170 12.9
Iowa 803 4,280 18.8 1,186 4,760 24.9 1,473 4,760 30.9 1,359 4,760 28.6
Kansas 556 5,570 10.0 751 5,060 14.8 944 5,060 18.7 859 5,060 17.0
Kentucky 781 13,170 5.9 1,244 12,990 9.6 1,669 12,990 12.8 1,510 12,990 11.6
Louisiana 2,458 15,490 15.9 3,574 15,920 22.4 4,221 15,920 26.5 3,390 15,920 21.3
Maine 318 3,270 9.7 494 3,950 12.5 658 3,950 16.7 601 3,950 15.2
Maryland 2,815 28,150 10.0 4,089 27,300 15.0 5,218 27,300 19.1 4,572 27,300 16.7
Massachusetts 5,996 25,110 23.9 8,191 24,900 32.9 10,212 24,900 41.0 9,356 24,900 37.6
Michigan 2,307 28,520 8.1 3,544 29,570 12.0 4,552 29,570 15.4 4,322 29,570 14.6
Minnesota 2,581 23,770 10.9 3,552 21,720 16.4 4,317 21,720 19.9 3,881 21,720 17.9
Mississippi 465 5,030 9.2 655 4,530 14.5 959 4,530 21.2 923 4,530 20.4
Missouri 1,983 19,420 10.2 2,850 18,370 15.5 3,634 18,370 19.8 3,414 18,370 18.6
Montana 123 2,750 4.5 185 2,290 8.1 272 2,290 11.9 272 2,290 11.9
Nebraska 361 2,590 13.9 481 2,180 22.1 637 2,180 29.2 656 2,180 30.1
Nevada 1,127 10,870 10.4 1,564 11,390 13.7 2,266 11,390 19.9 2,269 11,390 19.9
New Hampshire 338 3,110 10.9 533 3,020 17.6 656 3,020 21.7 600 3,020 19.9
New Jersey 3,457 28,590 12.1 4,768 25,280 18.9 5,955 25,280 23.6 5,489 25,280 21.7
New Mexico 618 6,720 9.2 820 6,800 12.1 1,100 6,800 16.2 1,098 6,800 16.1
New York 23,455 74,450 31.5 30,945 72,640 42.6 36,285 72,640 50.0 31,753 72,640 43.7
North Carolina 2,736 33,110 8.3 4,158 32,490 12.8 5,671 32,490 17.5 5,713 32,490 17.6
North Dakota 111 1,230 9.0 164 1,520 10.8 202 1,520 13.3 197 1,520 13.0
Ohio 3,645 40,940 8.9 4,931 40,320 12.2 6,393 40,320 15.9 6,200 40,320 15.4
Oklahoma 555 11,030 5.0 860 11,030 7.8 1,230 11,030 11.2 1,344 11,030 12.2
Oregon 2,073 20,720 10.0 2,757 19,750 14.0 3,396 19,750 17.2 3,369 19,750 17.1
Pennsylvania 6,326 36,160 17.5 8,800 36,490 24.1 10,546 36,490 28.9 9,828 36,490 26.9
Puerto Ricod 120 9,700 1.2 245 9,700 2.5 348 9,700 3.6 353 9,700 3.6
Rhode Island 657 4,360 15.1 897 3,880 23.1 1,133 3,880 29.2 1,086 3,880 28.0
South Carolina 720 10,390 6.9 1,249 10,390 12.0 1,788 10,390 17.2 1,884 10,390 18.1
South Dakota 60 1,000 6.0 104 910 11.4 151 910 16.6 127 910 14.0
Tennessee 1,802 22,890 7.9 2,691 22,460 12.0 4,020 22,460 17.9 4,511 22,460 20.1
Texas 11,750 123,400 9.5 18,050 123,790 14.6 23,898 123,790 19.3 24,867 123,790 20.1
Utah 1,045 6,900 15.1 1,500 6,840 21.9 2,029 6,840 29.7 2,078 6,840 30.4
Vermont 216 1,490 14.5 288 1,060 27.2 348 1,060 32.8 279 1,060 26.3
Virginia 2,167 33,670 6.4 3,267 31,430 10.4 4,686 31,430 14.9 4,747 31,430 15.1
Washington 6,952 35,600 19.5 8,986 40,050 22.4 10,864 40,050 27.1 10,567 40,050 26.4
West Virginia 242 3,660 6.6 380 5,250 7.2 610 5,250 11.6 490 5,250 9.3
Wisconsin 1,428 14,230 10.0 2,021 12,980 15.6 2,678 12,980 20.6 2,369 12,980 18.3
Wyoming 50 1,410 3.5 80 890 9.0 99 890 11.1 86 890 9.7

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2017 and 2018 data from National HIV Surveillance System, data from the National Health and Nutrition Examination Survey, and from U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dNumber of persons with PrEP indications in Puerto Rico is not avaible for 2017. 2018 data are used for 2017.

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2020, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions
Area of Residence 2017 2018 2019 2020 (January-September)
Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Persons prescribed PrEPa

No.

Persons with PrEP indicationsb

No.

PrEP coveragec

%

Arizona
Maricopa County 1,943 23,540 8.3 2,968 22,720 13.1 3,725 22,720 16.4 3,678 22,720 16.2
California
Alameda County 1,464 7,260 20.2 1,929 8,930 21.6 2,254 8,930 25.2 1,921 8,930 21.5
Los Angeles County 9,834 64,180 15.3 12,891 67,450 19.1 14,679 67,450 21.8 14,079 67,450 20.9
Orange County 1,084 9,990 10.9 1,640 10,510 15.6 2,123 10,510 20.2 2,041 10,510 19.4
Riverside County 1,022 11,040 9.3 1,454 11,080 13.1 1,861 11,080 16.8 1,804 11,080 16.3
Sacramento County 587 5,460 10.8 797 5,920 13.5 987 5,920 16.7 891 5,920 15.1
San Bernardino County 438 12,450 3.5 631 11,890 5.3 805 11,890 6.8 744 11,890 6.3
San Diego County 2,477 19,420 12.8 3,495 14,500 24.1 3,962 14,500 27.3 3,614 14,500 24.9
San Francisco County 6,597 11,330 58.2 8,176 10,840 75.4 9,170 10,840 84.6 7,828 10,840 72.2
District of Columbia 4,018 13,710 29.3 5,212 12,950 40.2 6,077 12,950 46.9 5,684 12,950 43.9
Florida
Broward County 2,011 20,030 10.0 2,913 20,470 14.2 3,881 20,470 19.0 5,720 20,470 27.9
Duval County 256 9,250 2.8 382 8,970 4.3 524 8,970 5.8 645 8,970 7.2
Hillsborough County 648 12,670 5.1 1,152 12,910 8.9 1,495 12,910 11.6 1,642 12,910 12.7
Miami-Dade County 2,018 22,190 9.1 3,891 21,760 17.9 6,668 21,760 30.6 8,869 21,760 40.8
Orange County 1,043 16,500 6.3 1,895 15,310 12.4 2,845 15,310 18.6 3,433 15,310 22.4
Palm Beach County 388 7,620 5.1 594 9,170 6.5 915 9,170 10.0 2,435 9,170 26.6
Pinellas County 470 10,470 4.5 800 9,530 8.4 1,133 9,530 11.9 1,064 9,530 11.2
Georgia
Cobb County 277 3,570 7.8 395 3,070 12.9 584 3,070 19.0 592 3,070 19.3
DeKalb County 916 6,370 14.4 1,229 6,290 19.5 1,616 6,290 25.7 1,580 6,290 25.1
Fulton County 2,018 12,060 16.7 2,667 13,120 20.3 3,403 13,120 25.9 3,297 13,120 25.1
Gwinnett County 320 3,390 9.4 468 3,240 14.4 714 3,240 22.0 724 3,240 22.3
Illinois
Cook County 8,905 38,270 23.3 11,812 39,060 30.2 14,027 39,060 35.9 12,069 39,060 30.9
Indiana
Marion County 692 8,490 8.2 880 9,150 9.6 1,171 9,150 12.8 1,066 9,150 11.7
Louisiana
East Baton Rouge Parish 225 1,290 17.4 452 1,810 25.0 514 1,810 28.4 488 1,810 27.0
Orleans Parish 1,061 5,230 20.3 1,387 4,590 30.2 1,669 4,590 36.4 1,255 4,590 27.3
Maryland
Baltimore City 475 6,000 7.9 666 6,330 10.5 930 6,330 14.7 813 6,330 12.8
Montgomery County 567 5,790 9.8 819 5,770 14.2 982 5,770 17.0 880 5,770 15.3
Prince George’s County 460 3,830 12.0 662 4,040 16.4 853 4,040 21.1 759 4,040 18.8
Massachusetts
Suffolk County 1,944 7,050 27.6 2,532 6,520 38.8 3,181 6,520 48.8 2,969 6,520 45.5
Michigan
Wayne County 695 9,470 7.3 1,045 9,270 11.3 1,293 9,270 13.9 1,143 9,270 12.3
Nevada
Clark County 958 8,790 10.9 1,320 11,670 11.3 1,944 11,670 16.7 1,921 11,670 16.5
New Jersey
Essex County 406 5,190 7.8 600 4,090 14.7 715 4,090 17.5 648 4,090 15.8
Hudson County 675 4,720 14.3 896 4,650 19.3 1,105 4,650 23.8 1,006 4,650 21.6
New York
Bronx County 1,335 6,690 20.0 2,045 5,570 36.7 2,305 5,570 41.4 1,848 5,570 33.2
Kings County 4,867 15,300 31.8 6,408 15,650 40.9 7,645 15,650 48.8 6,714 15,650 42.9
New York County 9,911 14,790 67.0 12,603 15,540 81.1 14,508 15,540 93.4 12,940 15,540 83.3
Queens County 2,634 8,740 30.1 3,412 9,230 37.0 4,020 9,230 43.6 3,562 9,230 38.6
North Carolina
Mecklenburg County 692 9,430 7.3 1,001 8,450 11.8 1,420 8,450 16.8 1,498 8,450 17.7
Ohio
Cuyahoga County 612 8,200 7.5 832 7,520 11.1 996 7,520 13.2 881 7,520 11.7
Franklin County 1,360 13,660 10.0 1,679 11,620 14.4 2,126 11,620 18.3 2,129 11,620 18.3
Hamilton County 280 6,430 4.4 449 7,720 5.8 570 7,720 7.4 567 7,720 7.3
Pennsylvania
Philadelphia County 2,475 8,550 28.9 3,306 9,840 33.6 3,781 9,840 38.4 3,224 9,840 32.8
Puerto Rico
San Juan Municipiod n/a 2,190 n/a n/a 2,190 n/a n/a 2,190 n/a n/a 2,190 n/a
Tennessee
Shelby County 319 7,590 4.2 480 6,450 7.4 656 6,450 10.2 691 6,450 10.7
Texas
Bexar County 676 13,010 5.2 1,140 11,920 9.6 1,529 11,920 12.8 1,562 11,920 13.1
Dallas County 2,366 22,000 10.8 3,354 28,670 11.7 4,325 28,670 15.1 4,685 28,670 16.3
Harris County 2,602 39,780 6.5 3,971 40,670 9.8 5,055 40,670 12.4 5,409 40,670 13.3
Tarrant County 698 11,550 6.0 1,197 11,340 10.6 1,513 11,340 13.3 1,486 11,340 13.1
Travis County 2,244 10,810 20.8 3,450 11,590 29.8 4,654 11,590 40.2 4,622 11,590 39.9
Washington
King County 5,072 13,690 37.0 6,360 17,890 35.6 7,669 17,890 42.9 7,520 17,890 42.0

Abbreviations: PrEP, preexposure propphylaxis; n/a, not available.

aEstimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2017 and 2018 data from National HIV Surveillance System, data from the National Health and Nutrition Examination Survey, and from U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dNumber of persons with PrEP indications in San Juan Municipio is not available in 2017. 2018 data are used for 2017.

Table 7. Ending the HIV Epidemic Phase I jurisdictions
Counties Territories States
Arizona Puerto Ricoa Alabama
Maricopa County San Juan Municipioa Arkansas
California Kentuckya
Alameda County Mississippi
Los Angeles County Missouri
Orange County Oklahoma
Riverside County South Carolina
Sacramento County
San Bernardino County
San Diego County
San Francisco County
District of Columbia
Florida
Broward County
Duval County
Hillsborough County
Miami-Dade County
Orange County
Palm Beach County
Pinellas County
Georgia
Cobb County
DeKalb County
Fulton County
Gwinnett County
Illinois
Cook County
Indiana
Marion County
Louisiana
East Baton Rouge Parish
Orleans Parish
Maryland
Baltimore City
Montgomery County
Prince George’s County
Massachusetts
Suffolk County
Michigan
Wayne County
Nevada
Clark County
New Jerseyb
Essex Countyb
Hudson Countyb
New York
Bronx County
Kings County
New York County
Queens County
North Carolina
Mecklenburg County
Ohio
Cuyahoga County
Franklin County
Hamilton County
Pennsylvaniaa
Philadelphia County
Tennessee
Shelby County
Texas
Bexar County
Dallas County
Harris County
Tarrant County
Travis County
Washington
King County

aLinkage to care and viral suppression data are not provided for states and associated counties that have incomplete reporting of laboratory data to CDC: Kansas, Kentucky, Pennsylvania (excuding Philadelphia County), Puerto Rico, and Vermont.
bLinkage to care and viral suppression data are not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads laboratory results: New Jersey.